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ABSTRACT
Gram-negative bacteria use N-acyl-homoserine lactone (AHL) autoinducer based
signal system, known as quorum sensing (QS), to modulate the gene expression for such
traits as biofilm formation, toxin production, and antibiotic resistance. Therefore, there is
great potential in pursuing quorum sensing inhibition (QSI) as a means of achieving
antivirulence. Pseudomonas aeruginosa, an opportunistic pathogen commonly found in
healthcare-related infections, use two LuxI/R type systems to regulate AHL-based
quorum sensing: LasI/R and RhlI/R. LasI (initiator protein/signal synthase) and LasR
(receptor) use 3-oxododecanoyl-L-homoserine lactone signal molecule while RhlI and
RhlR use butanoyl-L-homoserine lactone autoinducer. Thus far, most of the studies have
focused on inhibiting the Las system, in particular by using AHL signal analogs to
interfere with signal-receptor binding. Recently, RhlI/R system has gained attention as
potentially having greater effect in P. aeruginosa virulence. In this study, we have tested
the effect of AHL analogs on RhlI, as product inhibitors with the goal of targeting both
RhlI and RhlR for increased potency. Screening of compounds have revealed three
variations to have the greatest effect on RhlI inhibition: longer/bulkier acyl- chain, Dstereocenter in the headgroup, and a less polar thiolactone head-group. Surprisingly, the
addition of a carbonyl at the C3 position was found to activate the enzyme. Moreover, we
measured kinetic constants of RhlI with various acyl-substrates and performed inhibition
assays with inert acyl-substrate analogs to determine how RhlI activity changes to
variations in the acyl-chain length. We found that the catalytic efficiency of acyl-

v

substrate and inhibition potency of the corresponding inert acyl-substrate analogs surges
with increase in the length of the acyl-chain. These patterns suggest that long acyl-chains
most likely bind to an alternate binding site with marked increase in both kon and koff rate
constants. Our findings with AHL derivatives provide a basis for rational design of
quorum sensing inhibitors to better combat P. aeruginosa bacterial infections.

vi

TABLE OF CONTENTS

ACKNOWLEDGEMENTS ............................................................................................... iv
ABSTRACT .........................................................................................................................v
LIST OF TABLES ............................................................................................................. xi
LIST OF FIGURES .......................................................................................................... xii
LIST OF ABBREVIATIONS ........................................................................................ xviii
CHAPTER ONE: INTRODUCTION ..................................................................................1
The Antibiotic Crisis ................................................................................................1
Quorum Sensing.......................................................................................................3
Proposed AHL synthase mechanism ...........................................................8
RhlI, QS signal synthase in Pseudomonas aeruginosa ............................................9
AHL synthase Kinetics ..........................................................................................11
DCPIP Assay .............................................................................................11
Enzyme Kinetics ........................................................................................12
Thesis objective .....................................................................................................25
CHAPTER TWO: MATERIALS AND METHODS ........................................................31
Materials and Equipment .......................................................................................31
Methods..................................................................................................................33
HPLC Methods ..........................................................................................33
RhlI Purification.........................................................................................34

vii

Apo-ACP Purification ................................................................................36
Alkyl-CoA Synthesis .................................................................................37
Alkyl-/Acyl-ACP synthesis .......................................................................38
Purification of D-homocysteine thiolactone ..............................................40
Synthesis of N-acyl-D-homocysteine thiolactones ....................................41
Synthesis of N-(3-Oxoacyl)-D-homocysteine thiolactones .......................44
Mass Spectrometry.....................................................................................46
Kinetics Assays ..........................................................................................47
CHAPTER THREE: RESULTS AND DISCUSSION ......................................................52
Enzyme Purification...............................................................................................52
RhlI purification .........................................................................................52
Apo-ACP Purification ................................................................................53
Alkyl-CoA Synthesis .................................................................................53
Acyl/Alkyl-ACP Synthesis ........................................................................54
Small Molecule Synthesis ......................................................................................56
D-Homocysteine Thiolactone (Figure 19, Chapter 2) ...............................56
N-Acyl-D-Homocysteine Thiolactone (Figure 20, Chapter 2) ..................57
N-(3-Oxoacyl)-D-Homocysteine Thiolactone (Figure 21, Chapter 2) ......58
Spectral Data ..............................................................................................58
AHL Analog Kinetics ............................................................................................58
Background rate .........................................................................................58
The Effects of AHL analogs on RhlI enzymatic rate .................................59
Acyl-L-homoserine lactone (L-HSL) ........................................................60

viii

Acyl-D-homoserine lactone (D-HSL)........................................................61
3-oxoacyl-D-HSL ......................................................................................62
Acyl- and 3-oxoacyl-L-homocysteine thiolactone.....................................64
Acyl- and 3-oxoacyl-D-thiolactone ...........................................................65
Acyl-Cyclopentanamide ............................................................................66
Non-lactone derivatives .............................................................................67
Headgroup vs Tail chain effects ................................................................68
Determining the mode of inhibition...........................................................69
AHL analog Trends................................................................................................71
Chain length effect .....................................................................................71
Acyl-chain vs 3-oxoacyl-chain effects.......................................................73
Headgroup chirality effect .........................................................................76
Headgroup hydrophilicity effect ................................................................77
Determining Kinetic Constants with various Acyl-ACPs .....................................78
Alkyl-ACP Inhibition.............................................................................................83
Alkyl-CoA Inhibition .............................................................................................88
Conclusion .............................................................................................................89
REFERENCES ..................................................................................................................94
APPENDIX A ....................................................................................................................99
Mass Spectra ........................................................................................................100
APPENDIX B ..................................................................................................................109
NMR spectra ........................................................................................................110
APPENDIX C ..................................................................................................................130

ix

UV-Vis Spectra ....................................................................................................131

x

LIST OF TABLES

Table 1.

Types of QS signal molecules..................................................................... 6

Table 2.

Structures of 1st generation AHL-based small molecules tested for RhlI
inhibition. .................................................................................................. 26

Table 3.

Variations in the acyl-chains for 2nd generation of AHL-based small
molecules tested for RhlI inhibition.......................................................... 27

Table 4.

2nd generation of AHL-based small molecules tested for RhlI inhibition. 28

Table 5.

Nonlactone derivatives tested for RhlI inhibition ..................................... 29

Table 6.

Acyl-ACP, alkyl-ACP, and alkyl-CoA derivatives .................................. 29

Table 7.

Alkyl-CoA separation method .................................................................. 34

Table 8.

ACP separation method ............................................................................ 34

Table 9.

C6-ACP separation method ...................................................................... 34

Table 10.

Determining best fit model for the mode of inhibition using AIC ........... 71

Table 11.

Effect of AHL analogs on RhlI initial enzyme rate .................................. 71

Table 12.

Trends with variations in the acyl-chain length/size................................. 73

Table 13.

Patterns in varying effects of acyl- and 3-oxoacyl-chain derivatives. ...... 75

Table 14.

Effects of varying the headgroup chirality from L to D stereoisomer. ..... 76

Table 15.

The effect of headgroup hydrophobicity on RhlI inhibition. .................... 78

Table 16.

RhlI initial enzyme rate with various acyl-ACP substrates ...................... 81

Table 17.

Effect of IACP on RhlI initial enzyme rate. ............................................. 84

Table 18.

Determining best fit model for the mode of inhibition using AIC ........... 87

Table 19.

Effect of ICoA on RhlI initial enzyme rate ............................................... 89

xi

LIST OF FIGURES

Figure 1.

Timeline of the effective-lifetime of antibiotics ......................................... 2

Figure 2.

Decrease in new antibiotic development .................................................... 3

Figure 3.

The typical quorum sensing system found in Gram-negative bacteria ....... 5

Figure 4.

Species-specific signal molecules. .............................................................. 6

Figure 5.

The proposed mechanism of AHL-synthases ............................................. 8

Figure 6.

QS system regulation in P. aeruginosa..................................................... 11

Figure 7.

DCPIP assay mechanism .......................................................................... 12

Figure 8.

The Substrate-Velocity Curve................................................................... 13

Figure 9.

Typical Lineweaver-Burk plot .................................................................. 14

Figure 10.

Kinetic mechanism for bisubstrate enzyme .............................................. 15

Figure 11.

Double reciprocal plot of sequential vs ping-pong reaction mechanism. . 17

Figure 12.

Cleland diagram of RhlI catalyzed ordered bi-ter reaction ....................... 17

Figure 13.

Modes of inhibition ................................................................................... 19

Figure 14.

Representative IC50 curve ......................................................................... 23

Figure 15.

Representative EC50 curve ........................................................................ 25

Figure 16.

Structures of Acyl-ACP and CoA ............................................................. 30

Figure 17.

Synthesis of alkyl-CoA ............................................................................. 38

Figure 18.

Sfp catalyzed acyl-pantetheine transfer reaction ....................................... 39

Figure 19.

Purification of pure D-homocysteine thiolactone ..................................... 41

Figure 20.

Acylation of D-thiolactone headgroup...................................................... 42

xii

Figure 21.

Synthesis and purification of 3oxoacyl-D-thiolactones ............................ 45

Figure 22.

SDS-PAGE gel of RhlI protein ................................................................. 52

Figure 23.

SDS-PAGE gel of apo-ACP ..................................................................... 53

Figure 24.

Elution time of various alkyl-CoAs .......................................................... 54

Figure 25.

Elution time of various acyl-/alkyl-ACPs ................................................. 56

Figure 26.

DCPIP background rate progress curve .................................................... 59

Figure 27.

Initial set of AHL-analogs and their effects .............................................. 60

Figure 28.

Effects of acyl-L-homoserine lactones ..................................................... 61

Figure 29.

Effects of acyl-D-homoserine lactones ..................................................... 62

Figure 30.

Effects of 3-oxoacyl-D-homoserine lactones............................................ 63

Figure 31.

Effects of L and D sulfonamides .............................................................. 63

Figure 32.

Effects of acyl- and 3-oxoacyl-L-homocysteine thiolactones .................. 64

Figure 33.

Effects of acyl- and 3-oxoacyl-D-homocysteine thiolactones .................. 66

Figure 34.

Effects of acyl-cyclopentanamide on RhlI activity ................................... 67

Figure 35.

Effects of non-lactone AHL analogs on RhlI activity .............................. 68

Figure 36.

Effects of headgroup and tail moieties in isolation on RhlI initial rate .... 69

Figure 37.

Cleland diagram of RhlI catalyzed reaction.............................................. 70

Figure 38.

Double Reciprocal Plot of RhlI activity with varying C4-ACP
concentrations and various fixed AHL analog concentrations ................. 71

Figure 39.

Substrate-velocity curves of RhlI with native and nonspecific acyl-ACP
substrates ................................................................................................... 80

Figure 40.

Trends in kcat, Km, and kcat/Km values of RhlI with various acyl substrates
................................................................................................................... 81

Figure 41.

Alignment of amino acid sequence of P. aeruginosa ACP1, ACPP, ACP3,
and E. coli ACP......................................................................................... 83

xiii

Figure 42.

Various AHL products of LasI ................................................................. 83

Figure 43.

Designing inactive acyl-ACP analog ........................................................ 84

Figure 44.

IC50 test of various IACPs......................................................................... 85

Figure 45.

Double Reciprocal Plot of RhlI activity with varying C4 -CP
concentrations and various fixed IACP concentrations ............................ 87

Figure 46.

Time-dependency of IACP inhibition....................................................... 88

Figure 47.

IC50 test of various ICoAs ......................................................................... 89

Figure 48.

Moieties of interest for improved AHL-based RhlI modulators ............... 90

Figure 49.

Specificity vs. Potency in targeting RhlI. ................................................. 91

Figure A1.

Mass Spectrum of Compound 56 ............................................................ 100

Figure A2.

Mass Spectrum of Compound 57 ............................................................ 100

Figure A3.

Mass spectrum of Compound 58 ............................................................ 101

Figure A4.

Mass Spectrum of Compound 59 ............................................................ 101

Figure A5.

Mass Spectrum of Compound 60 ............................................................ 102

Figure A6.

Mass Spectrum of Compound 61 ............................................................ 102

Figure A7.

Mass Spectrum of Compound 62 ............................................................ 103

Figure A8.

Mass Spectrum of Compound 63 ............................................................ 103

Figure A9.

Mass Spectrum of Compound 64 ............................................................ 104

Figure A10.

Mass Spectrum of Compound 88 ............................................................ 104

Figure A11.

Mass Spectrum of Compound 89 ............................................................ 105

Figure A12.

Mass Spectrum of Compound 90 ............................................................ 105

Figure A13.

Mass Spectrum of Compound 91 ............................................................ 106

Figure A14.

Mass Spectrum of Compound 92 ............................................................ 106

Figure A15.

Mass Spectrum of Compound 93 ............................................................ 107

xiv

Figure A16.

Mass Spectrum of Compound 94 ............................................................ 107

Figure A17.

Mass Spectrum of Compound 95 ............................................................ 108

Figure B1.

D-homocysteine thiolactone 1H NMR .................................................... 110

Figure B2.

Compound 56 1H NMR .......................................................................... 110

Figure B3.

Compound 56 COSY NMR .................................................................... 111

Figure B4.

Compound 56 HSQC NMR .................................................................... 111

Figure B5.

Compound 56 HMBC NMR ................................................................... 112

Figure B6.

Compound 56 13C NMR ......................................................................... 112

Figure B7.

Compound 57 1H NMR .......................................................................... 113

Figure B8.

Compound 57 COZY NMR .................................................................... 113

Figure B9.

Compound 57 13C NMR ......................................................................... 114

Figure B10.

Compound 58 1H NMR .......................................................................... 114

Figure B11.

Compound 58 COSY NMR .................................................................... 115

Figure B12.

Compound 58 HSQC NMR .................................................................... 115

Figure B13.

Compound 58 HMBC NMR ................................................................... 116

Figure B14.

Compound 58 13C NMR ......................................................................... 116

Figure B15.

Compound 59 1H NMR .......................................................................... 117

Figure B16.

Compound 59 COSY NMR .................................................................... 117

Figure B17.

Compound 59 HSQC NMR .................................................................... 118

Figure B18.

Compound 59 HMBC NMR ................................................................... 118

Figure B19.

Compound 59 13C NMR ......................................................................... 119

Figure B20.

Compound 60 1H NMR .......................................................................... 119

Figure B21.

Compound 60 COSY NMR .................................................................... 120

xv

Figure B22.

Compound 60 HSQC NMR .................................................................... 120

Figure B23.

Compound 60 HMBC NMR ................................................................... 121

Figure B24.

Compound 60 13C NMR ......................................................................... 121

Figure B25.

Compound 61 1H NMR .......................................................................... 122

Figure B26.

Compound 61 COSY NMR .................................................................... 122

Figure B27.

Compound 61 HSQC NMR .................................................................... 123

Figure B28.

Compound 61 HMBC NMR ................................................................... 123

Figure B29.

Compound 61 13C NMR ......................................................................... 123

Figure B30.

Compound 62 1H NMR .......................................................................... 124

Figure B31.

Compound 62 COSY NMR .................................................................... 124

Figure B32.

Compound 62 HSQC NMR .................................................................... 125

Figure B33.

Compound 62 HMBC NMR ................................................................... 125

Figure B34.

Compound 62 13C NMR ......................................................................... 125

Figure B35.

Compound 63 1H NMR .......................................................................... 126

Figure B36.

Compound 63 COSY NMR .................................................................... 126

Figure B37.

Compound 63 HSQC NMR .................................................................... 127

Figure B38.

Compound 63 HMBC NMR ................................................................... 127

Figure B39.

Compound 64 13C NMR ......................................................................... 127

Figure B40.

Compound 64 1H NMR .......................................................................... 128

Figure B41.

Compound 64 COSY NMR .................................................................... 128

Figure B42.

Compound 64 HSQC NMR .................................................................... 129

Figure B43.

Compound 64 HMBC NMR ................................................................... 129

Figure B44.

Compound 64 13C NMR ......................................................................... 129

xvi

Figure C1.

IC50 of First generation of AHL analogs................................................. 131

Figure C2.

IC50 of L-HSL derivatives ....................................................................... 132

Figure C3.

IC50 of acyl-D-HSL analogs.................................................................... 133

Figure C4.

IC50 and EC50 of 3-oxoacyl-D-HSL analogs ........................................... 133

Figure C5.

IC50 of DL-sulfonamide analog .............................................................. 134

Figure C6.

IC50 of acyl- and 3-oxoacyl-L-homocysteine thiolactones ..................... 135

Figure C7.

IC50 and EC50 of acyl- and 3oxoacyl-D-homocysteine thiolactones ...... 136

Figure C8.

IC50 of cyclopentyl derivatives ............................................................... 136

Figure C9.

IC50 of non-lactone AHL analogs ........................................................... 137

Figure C10.

IC50 of headgroup and tail moieties ........................................................ 138

Figure C11.

Substrate-velocity curve of RhlI with various acyl-ACP substrates ....... 139

Figure C12.

IC50 of various alkyl-ACPs ..................................................................... 139

Figure C13.

RhlI Inhibition assays with various alkyl-ACPs ..................................... 140

Figure C14.

Double reciprocal plot for RhlI inhibition with various alkyl-ACPs ...... 140

Figure C15.

IC50 of IACPs at different time points ................................................... 141

Figure C16.

IC50 of ICoA derivatives ......................................................................... 141

Figure C17.

DMSO Inhibition .................................................................................... 141

xvii

LIST OF ABBREVIATIONS
CDC

Center for Disease Control and Prevention

WHO

World Health Organization

QS

Quorum Sensing

QSI

Quorum Sensing Inhibition

AHL

N-Acyl-Homoserine Lactone

AI-1

Autoinducer-1

SAM

S-adenosyl-L-methionine

ACP

Acyl Carrier Protein

Apo-ACP

Apo-Acyl Carrier Protein

Acyl-ACP

Acyl-Acyl Carrier Protein

CoA

Coenzyme A

Acyl-CoA

Acyl-Coenzyme A

AIP

Autoinducer Peptide

AI-2

Autoinducer-2

MTA

5′-Deoxy-5′-methylthioadenosine

PQS

Pseudomonas Quinolone Signal

HSL

Homoserine lactone

3oxoC12-HSL

3-Oxododecanoyl-homoserine lactone

C4-HSL

Butanoyl-homoserine lactone

DCPIP

2,6-Dichloroindophenol

xviii

V

Enzyme initial rate

Vmax

Maximum enzyme initial rate

Km

Michaelis constant

kcat

Turnover rate

Ki

Inhibition constant

[S]

Substrate concentration

[I]

Inhibitor concentration

AIC

Akaike’s Information Criterion

IC50

Half maximal inhibitory concentration

EC50

Half maximal effective concentration

Alkyl-ACP

Alkyl-Acyl Carrier Protein

Alkyl-CoA

Alkyl-Coenzyme A

MPA

(S)-(+)-α-Methoxyphenylacetic acid

MES

2-(N-Morpholino)ethanesulfonic acid hydrate

Meldrum’s acid

2,2-Dimethyl-1,3-dioxane-4,6-dione

HEPES

4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid

EDTA

Ethylenediaminetetraacetic acid

MgSO4

Magnesium sulfate anhydrous

EDC

N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride

TLCK

Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride

PMSF

Phenylmethanesulfonyl fluoride

C4-CoA

Butanoyl-CoA

xix

C6-CoA

Hexanoyl-CoA

C8-CoA

Octanoyl-CoA

C10-CoA

Decanoyl-CoA

C12-CoA

Dodecanoyl-CoA

DNase

Deoxyribonuclease I

RNase

Ribonuclease I

IPA

2-Propanol

B-PER

Bacterial protein extraction reagent

DMF

Dimethylformamide

DMSO

Dimethyl sulfoxide

HCl

Hydrochloric acid

IPTG

Isopropyl β-D-1-thiogalactopyranoside

MnSO4

Manganese sulfate

TFA

Trifluoroacetic acid

MgCl2

Magnesium chloride

kD

Kilodalton

Sfp

Surfactin-synthetase activating
protein/phosphopantetheinyl transferase

UV-Vis

Ultraviolet-visible light

HPLC

High performance liquid chromatography

UHPLC

Ultra high performance liquid chromatography

QTOF

Quadrupole time-of-flight

ACN

Acetonitrile

xx

Buffer A

50 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 1 mM EDTA, 0.1
mM PMSF, 0.1 mM TLCK, 0.4 M sucrose, and 2.5% (v/v)
glycerol

Psi

Pounds per square inch

OD600

Optical density at 600 nm

w/v

weight to volume ratio

RT

Retention time

C6-ACP

Hexanoyl-ACP

C4-ACP

Butanoyl-ACP

IACP

Inert-ACP/alkyl-ACP

C4-IACP

Butyl-ACP

C6-IACP

Hexyl-ACP

C8-ACP

Octanoyl-ACP

C8-IACP

Octyl-ACP

C10-ACP

Decanoyl-ACP

C10-IACP

Decyl-ACP

C12-ACP

Dodecanoyl-ACP

NaHCO3

Sodium bicarbonate

KHSO4

Potassium bisulfate

HPLC-MS

High performance liquid chromatography mass
spectrometry

MS

Mass spectrometry

LC-MS

Liquid chromatography-mass spectrometry

xxi

ESI

Electrospray ionization

LC

Liquid chromatography

TLC

Thin layer chromatography

3-oxoC8-D-HSL

3-Oxooctanoyl-D-homoserine lactone

3-oxoC6-D-HSL

3-Oxohexanoyl-D-homoserine lactone

C12-D-thiolactone

Dodecanoyl-D-homocysteine thiolactone

3-oxoC12-D-thiolactone

3-Oxododecanoyl-D-homoserine lactone

C12-L-thiolactone

Dodecanoyl-L-homocysteine thiolactone

3-oxoC12-L-thiolactone

3-Oxododecanoyl-L-homoserine lactone

3-oxoC6-D-thiolactone

3-Oxohexanoyl-D-homoserine lactone

3-oxoC8-D-thiolactone

3-Oxooctanoyl-D-homoserine lactone

3-oxoC10-D-thiolactone

3-Oxodecanoyl-D-homoserine lactone

C4-ICoA

Butyl-CoA

C6-ICoA

Hexyl-CoA

C8-ICoA

Octyl-CoA

xxii

1

CHAPTER ONE: INTRODUCTION
The Antibiotic Crisis
The modern age of medicine was made possible, in large parts, by the discovery
and the proliferation of antibiotics. However, mankind has been slowly disarmed by the
rise and the spread of antibiotic resistant superbugs. In the U.S. alone, antibiotic-resistant
bacteria are responsible for at least two million infections, resulting in 23,000 lives and
cost $35 billion annually.1 In response to this rise in antibiotic resistance, the White
House has named it a threat to national security.2 Despite efforts to curb the tide, both
CDC and WHO warn of a post-antibiotic age.1, 3
The rise of superbugs highlights a fundamental problem with antibiotics; the use
of antibiotics is an all-or-nothing treatment in which all the drug-sensitive strains are
eliminated while the resistant ones are untouched. This dichotomy places enormous
selective pressure for resistant bacteria to propagate throughout the entire population. In a
controlled environment, a strain of sensitive bacteria can be pressured to withstand everincreasing concentrations of antibiotics in less than two-weeks.4 Even in the real-world
setting, resistance often develops within a few years of the release of a new antibiotic
(Figure 1).5 Therefore, drug companies are shying away from continuing to put resources
into R&D of a drug that could become irrelevant soon after its commercialization (Figure
2).6, 7 The resulting decrease in supply combined with the increase in demand have led to
the investigation of novel methods to fight bacteria, such as predatory bacteria,
bacteriophage, antimicrobial peptides, gene-editing enzymes, and quorum sensing.8-13 Of
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these alternatives, most follow the pattern of antibiotics in that they kill sensitive strains,
leaving behind resistant strains to flourish; however, quorum sensing (QS) provide a
unique means of avoiding the pitfalls of antibiotics by targeting virulence rather than the
organism directly.14

Figure 1.5
Timeline of the effective-lifetime of antibiotics. The labels above the
timeline indicates the year different antibiotics were released, whereas the year resistance
to each antibiotic was first observed is shown below the timeline. In many cases,
resistance developed within a few years of deployment of new antibiotics.
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Figure 2.
Decrease in new antibiotic development. In the heydays of antibiotic
development in the 1980’s, more than 3 new drugs were released annually; however, in
recent years, that number has been reduced to just two new antibiotics in five years.
Quorum Sensing
Once known mainly for their single-cellular life, bacteria are now known to
communicate via chemical signals to approximate multicellular behavior in a process
termed quorum sensing.15 The concentration of the signal molecules, called
autoinducers, correlate to the number of bacteria in the area. Therefore, by monitoring the
concentrations of the autoinducers, bacteria can detect the concentration of local bacteria
population.16, 17 Typically, when signal concentration is low, indicative of limited cell
count, bacteria operate individually. However, once a certain concentration, or “quorum,”
is reached, QS-controlled genes are turned on, activating group behaviors, which includes
biofilm formation, virulence, antibiotic resistance, protease production, and
siderophores.18 Therefore, theoretically, QS inhibitors could be used as combination drug
with antibiotics since antibiotic resistance associated with QS inhibition (QSI) would be
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reduced. Additionally, inhibiting quorum sensing should prevent virulent traits from
emerging.19 Indeed, studies have shown QS-knockout strains to be incapable of colonial
behaviors characteristic of pathogenicity.20 As an anti-virulence treatment, contrary to
the lethal (to the bacteria) antibiotic therapy, QS inhibition (QSI) could potentially pave
the path to an “evolution-proof” method of dealing with bacterial infections.19 It has
been shown that QSI resistance does not lead to survival advantage. The study showed
that since the majority of the population are unable to produce autoinducer signal
molecules, the few resistant strains could not produce sufficient AHLs to reach “quorum”
and induce QS-controlled gene expression; however, even if the resistance strains are
able to express QS-controlled traits, many of which are group-beneficial, the benefits of
those traits are shared with the inhibited strains, thus limiting any survival advantage QSI
resistance could offer.19
Quite contrary to the notion of being “simple” creatures, bacteria have complex
communication system with different QS system for various types of bacteria. Gramnegative bacteria have LuxI (initiator/synthase) and LuxR (receptor) type proteins
responsible for the synthesis and the uptake of N-acyl-homoserine lactone (AHL/AI-1)
autoinducers (Figure 3; Table 1). In this communication system, AHL synthases release
AHL autoinducers and release them to the environment. The binding of the signal with
the designated receptor protein starts the upregulation of QS-controlled genes such as
increased AHL synthase activity, biofilm formation, toxin production, and antibiotic
resistance.
AHL synthases are bi-substrate enzymes that use S-adenosyl-L-methionine
(SAM) and an acyl substrate (acyl-ACP or acyl-CoA) to synthesize AHL signal
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molecule. Whereas SAM is a conserved substrate among various AHL synthases,
preferential usage of an acyl substrate of certain acyl-chain moiety results in enzymespecific signal molecules, allowing each species to speak its own unique “language,” or
differentiated AHLs (Figure 4).21 Many AHL synthases have been shown to discriminate
against non-native acyl-chain and only use a specific acyl substrate to produce enzymespecific AHL signal, thus increasing the signal to noise ratio.22 Different receptor
proteins likewise preferentially bind with their designated AHLs so that bacteria can
conduct intra-specie communication without interference.

Figure 3.
The typical quorum sensing system found in Gram-negative bacteria.
A LuxI-type signal synthase produces AHL signal molecules which then binds to LuxRtype receptor proteins. The signal-receptor binding promotes the expression of QScontrolled genes, which includes further activation of the synthase.
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Figure 4.
Species-specific signal molecules. The different “languages” used by
each Gram-negative bacteria species are dependent on the variations in the acyl-chain
which is derived from the acyl substrate.
Table 1.

Types of QS signal molecules

Signal Type

Organism

AI-1/AHL

Gram-negative

Structure

C

Cys

Ser

AIP

O

S

Thr

Tyr

Gram-positive

Met
Asp
Phe

H3C

AI-2

Universal

O

O
-

HO B O
HO

OH
OH

Ile
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Gram-positive bacteria, on the other hand, use short peptides, linear or cyclic, as
QS signals (Table 1). As with Gram-negative QS system, the specificity comes from
varying the signal molecules by modifying the peptide sequence and shape.23
Synthesized in the cytoplasm and actively transported out of the cell, these autoinducer
peptides (AIP) bind to membrane-bound histidine kinase, leading to a phosphorylation
cascade, activating QS regulator proteins for gene expression.24
In addition to the species-specific AHL/AI-1 and AIP based QS for interspeciescommunications, a universal signal-based QS system has also been discovered. This
interspecies-communication QS is based on AI-2 signal molecule (Table 1). Like the
AIP-based system, AI-2 binding event starts a phosphorylation cascade to regulate gene
expression.25
In light of the antibiotic crisis, of these three systems (AHL, AIP, AI-2), AHLbased QS found in human-pathogen-causing Gram-negative bacteria is of great interest.
Four-main principles of targeting AHL communication system have been proposed:
synthase inhibition, receptor inhibition, quorum-quenching enzymes, and AHLsequestering antibodies.26-29 Most studies thus far have explored receptor inhibition;
however, due to high affinity of native AHLs to AHL-receptor proteins, it is a difficult
task to design a molecule that could out compete the binding of native autoinducer to
LuxR-type proteins to disrupt QS.30-33 The progress towards developing synthase
inhibitors, on the other hand, is hampered because most AHL synthases are yet to be
characterized. Nevertheless, AHL synthase-knockout studies have led to elimination of
virulence traits, supporting AHL synthase modulation as a means of QS control.34
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Efforts toward understanding the mechanism of AHL synthesis are important to design
potent and selective AHL synthase inhibitors.
Proposed AHL synthase mechanism
AHL synthases are bi-ter enzymes that catalyzes the conversion of S-adenosyl-Lmethionine (SAM) and acyl-acyl-carrier protein (acyl-ACP) or acyl-coenzyme A (acylCoA) to AHL autoinducer, 5′-deoxy-5′-methylthioadenosine (MTA), and holo-ACP or
free-CoA (Figure 5).35-38 During catalysis, nucleophilic attack from the amine group of
SAM to the carbonyl carbon of acyl-ACP cleaves the thioester bond, thereby releasing
holo-ACP and transferring the fatty acid tail to SAM in the acylation half-reaction. In the
lactonization reaction, SAM undergoes intramolecular ring closure, forming the lactone
head-group and producing MTA side product.

Figure 5.
The proposed mechanism of AHL-synthases. SAM is a conserved
substrate amongst all AHL synthases. The variation comes from the R-group of the acyl
substrate.
As with any other enzyme, AHL synthases can be inhibited by interference in the
substrate binding, the catalysis, or the product release steps. However, each approach has
its corresponding challenges. To disrupt substrate binding, substrate analogs would be the
ideal starting point, yet SAM and acyl-ACP are commonly used in human enzymes,
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SAM as a common methyl donor and acyl-ACP as a key player in fatty-acid
biosynthesis.39, 40 Therefore, SAM or acyl-ACP based design of inhibitors have the
potential to target all SAM or acyl-ACP using enzymes, thereby increasing the risk of
unwanted side-effects. Moreover, how an AHL synthase preferentially bind to its native
substrate over similarly shaped analogs, such as acyl-ACPs of different chain length, is
not well understood, which impedes the design of substrate analogs that would outcompete the native substrates binding to the enzyme. Mechanism-based covalent
inhibitors act by forming covalent bonds with certain active site residues; however, as
most AHL synthases remain uncharacterized the active site residues to target remain
unknown.
As holo-ACP and MTA are both relevant in human biology, holo-ACP in fatty
acid synthesis and MTA in polyamine synthesis, product inhibitors based on those
compounds carry the dangers of serious side-effects.41, 42 AHL-based inhibitors, on the
other hand, has qualities suitable for pharmaceutical uses; AHL-analogs would have the
potential of targeting both the synthase and the receptor, be QS-specific, have favorable
cell-membrane diffusion characteristics, and have long shelf-life.30, 31, 33 There have been
no reports of AHL-based modulators tested on AHL-synthases; however, studies reveal
their great effect on AHL receptors, both as agonists and antagonists.43-45
RhlI, QS signal synthase in Pseudomonas aeruginosa
Pseudomonas aeruginosa is a specie of common Gram-negative bacteria that can
cause diseases in both animals and plants. It is categorized as opportunistic bacteria
commonly associated with healthcare-associated infections, infecting 51,000 every year
in American hospitals, killing 400.46 In humans, it can cause pneumonia, cystic fibrosis,
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bacterial meningitis, septic shock, urinary tract infection, GI infection, and skin and soft
tissue infections.6, 46, 47 P. aeruginosa infections are becoming harder to treat due their
increasing resistance to antibiotics, so much so that the CDC labeled it as a “serious
threat” in their report on “Antibiotic Resistance Threats in the United States, 2013.”46
The virulence and antibiotic resistance in P. aeruginosa is controlled by its QS
system comprised of AHL-quinolone system. Its AHL system is comprised of LasI/R and
RhlI/R systems whereas the Pseudomonas quinolone signal (PQS) is under Pqs receptor
(PqsR) control (Figure 6).48 The two AHL-based systems use very different signal
molecules. LasI synthesizes 3-oxo-dodecanoyl-homoserine lactone (3OC12HSL) signal
molecule, which binds with LasR to activate several QS-controlled genes, which includes
the Rhl and Pqs system. The RhlI/R proteins, in contrast, use butanoyl-homoserine
lactone (C4HSL) autoinducers as the signal molecule. Under normal conditions, LasI/R
pair is thought to activate the Rhl and the Pqs system, though both the Rhl and the Pqs
have been observed acting independent of the Las system under certain circumstances.
Furthermore, Pqs generally activates Rhl whereas Rhl typically suppresses Pqs via
mechanisms not completely understood. Studies have shown that inhibiting any of these
three QS systems significantly reduces Pseudomonas aeruginosa virulence. Studies thus
far have focused primarily on Las-system inhibition and Rhl-specific inhibitors have yet
to be studied in great detail. However, Rhl-system inhibition merit further examination
for Rhl knockout strains strain to display pathogenic phenotype.49, 50
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Figure 6.48
QS system regulation in P. aeruginosa. LasI/R promotes both the Rhl
and Pqs systems. Whereas Pqs induces Rhl activity, Rhl inhibits Pqs via unknown
methods.
AHL synthase Kinetics
DCPIP Assay
DCPIP colorimetric assay is a well-established assay used to determine AHL
synthase activity by monitoring the enzyme-dependent rate of release of holo-ACP/CoA
thiol product over time (Figure 7).51-53 DCPIP, in its oxidized form, is a blue compound
that absorbs at 600 nm (ε600 = 21,000 M-1cm-1 = 2.1 x 10-2 µM-1 cm-1). The holo-ACP
thiol released upon acylation of SAM reduces the DCPIP dye to a colorless form,
DCPIPH2. By monitoring the change in the absorbance of DCPIP at 600 nm, the enzyme
rate can be determined by the following equation:
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Figure 7.
DCPIP assay mechanism. DCPIP, in its oxidized form, is a blue
compound that turns colorless upon reduction with two thiols released from acylation
reaction in AHL synthesis. By monitoring the decrease of absorbance at 600 nm, AHL
synthase rate can be determined.
Enzyme Kinetics
Initial rate of enzyme activity as a function of substrate concentration follows a
hyperbolic curve (Figure 8). When the substrate is present in saturating concentrations,
maximum initial rate is achieved, denoted by Vmax. The concentration of the substrate
required to reach half-maximal velocity is termed Km.
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Figure 8.
The Substrate-Velocity Curve. This curve represents the relationship of
enzyme rate as a function of substrate concentration.
This plot, also called the substrate-velocity curve, is commonly analyzed using
the Michaelis-Menten equation. In the simplest situation where one substrate is converted
to one product, the reaction can be summarized as:
𝑣

𝐸 + 𝑆 ⇌ 𝐸𝑆 → 𝐸 + 𝑃

(4)

where E is the enzyme, S the substrate, ES the enzyme-substrate complex (Michaelis
complex), P the product, and v the reaction rate. The rate of the reaction (v) can be
described with the equation:
𝑉=

𝑉𝑚𝑎𝑥 [𝑆]
[𝑆]+𝐾𝑚

(5)

where Vmax is the highest reaction rate that the enzyme can achieve at saturating substrate
concentration, [S] the substrate concentration, and Km the substrate concentration
required for half-maximal rate. The Vmax and Km of an enzyme can be determined by
measuring the initial enzyme rate with various substrate concentrations and fitting the
resulting plot with the Michaelis-Menten equation. For easier interpretation, this
hyperbolic curve can be linearized by taking the inverse of both sides of the equation,
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thereby converting the Michaelis-Menten equation to the double-reciprocal or
Lineweaver-Burke equation (Figure 9):
1
𝑉

=

𝐾𝑚
𝑉𝑚𝑎𝑥

[𝑆] +

1

(6)

𝑉𝑚𝑎𝑥

where independent axis (x-axis) represents the substrate concentration and the dependent
axis (y-axis), the inverse rate. In this form, a change in the Vmax would lead to a shift in
𝐾𝑚

the y-intercept (intercept-effect) and a change in the 𝑉

𝑚𝑎𝑥

(inverse of catalytic efficiency,

kcat/Km) ratio would cause a change in the slope (slope-effect).

Figure 9.
Typical Lineweaver-Burk plot. Taking the inverse of the hyperbolic
Michaelis-Menten plot linearizes the data. In the 1/V vs 1/[S] plot, the y-intercept
corresponds to 1/Vmax, the x-intercept to -1/Km, and the slope to Km/Vmax.
However, AHL synthases are bi-ter enzymes (2 substrates, 3 products). The order
of substrate binding and product release (the kinetic mechanism) can follow one of three
patterns (Figure 10). 1) Ordered sequential mechanism: substrates bind to the enzyme in a
specific order before the products are released in a defined sequence. 2) Random
sequential mechanism: substrates all bind before the first product is released but the
order of substrate addition or the product release, or both, is random. 3) Ping-pong
sequential mechanism: the first product is released before the second substrate binds
with the enzyme.
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Figure 10.
Kinetic mechanism for bisubstrate enzyme. (a) Ordered sequential:
substrate binding occurs before product release and follow definite order. (b) Random
sequential: substrate binding occurs before product release and follow random order. (c)
Ping-pong: first product release step occurs before the second substrate addition.
Bi-substrate enzyme kinetics is represented by a more complicated Cleland
equation as shown:
𝑣=

𝑉𝑚𝑎𝑥 [𝐴][𝐵]
𝐵 [𝐴]+𝐾 𝐴 [𝐵]+[𝐴][𝐵]
𝐾+𝐾𝑚
𝑚

(7)

where KmA is the Michaelis constant for substrate A at saturating concentrations of B,
KmB the Michaelis constant for substrate B at saturating concentrations of A, and K
depends on the reaction type (sequential vs ping-pong). In a sequential mechanism, the
Cleland equation becomes:
𝑣=

𝑉𝑚𝑎𝑥 [𝐴][𝐵]
𝐵 +𝐾 𝐵 [𝐴]+𝐾 𝐴 [𝐵]+[𝐴][𝐵]
𝐾𝑖𝐴 𝐾𝑚
𝑚
𝑚

(8)
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where the KiA is the dissociation constant for the EA complex in the absence of the
second substrate, B. If the enzyme undergoes ping-pong mechanism, the K term drops
and the Cleland equation becomes:
𝑣=

𝑉𝑚𝑎𝑥 [𝐴][𝐵]

(9)

𝐵 [𝐴]+𝐾 𝐴 [𝐵]+[𝐴][𝐵]
𝐾𝑚
𝑚

The double reciprocal of the Cleland equation for sequential mechanism is:
1

=

𝑉

1
𝑉𝑚𝑎𝑥

𝐾𝐵

1

𝐾𝐵

1

𝐾𝑏

𝑚
𝑚
[(1 + [𝐵]
) + [𝐴] (𝐾𝑚𝐴 + 𝐾𝑖𝐴 ∙ [𝐵]
)]

(10)

and for the ping-pong mechanism:
1

=

𝑉

1
𝑉𝑚𝑎𝑥

𝑚
[(1 + [𝐵]
) + [𝐴] (𝐾𝑚𝐴 )]

(11)

at constant [B] and variable [A], the slope of sequential equation is:
1
𝑉𝑚𝑎𝑥

𝐾𝑏

𝑚
(𝐾𝑚𝐴 + 𝐾𝑖𝐴 ∙ [𝐵]
)

(12)

which indicates that the slope depends on the concentration of substrate B (slope-effect).
For the ping-pong equation, the slope is:
𝐴
𝐾𝑚

(13)

𝑉𝑚𝑎𝑥

indicating that the slope is independent of the substrate B concentration (no slope-effect).
For both the sequential and the ping-pong mechanism equation, the intercept of this is:
1
𝑉𝑚𝑎𝑥

𝐾𝐵

𝑚
(1 + [𝐵]
)

(14)

showing that the intercept always depends on B concentration (intercept-effect). This
dependence on [B] indicates that saturation with A does not cut off the effect of adding
more B. Therefore, at saturating A concentration, the addition of B always increases the
rate (increases the apparent Vmax).
For sequential mechanism, since both the slope and the intercept are dependent
1

on the fixed concentration of substrate B, the double reciprocal plot of V vs

1
[A]

at various
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fixed [B] would feature a set of lines intersecting in quadrant II (Figure 11 a). For pingpong mechanism, since only the intercept is affected by the concentration of B, the
1

double reciprocal plot of V vs

1
[A]

at various fixed [B] would feature a set of parallel lines

(Figure 11 b).

Figure 11.
Double reciprocal plot of sequential vs ping-pong reaction
mechanism. Enzyme reactions at various fixed B concentrations and varying A
concentration are observed. (a) If A and B both bind before product release, sequential
addition, both the slope and the intercept drop as [B] increases and the lines intersect in
the second quadrant. (b) If the enzyme follows ping-pong mechanism, only the intercept
decreases as [B] increases and the lines remain parallel.
Work by Greenberg showed that RhlI is an ordered bi-ter enzyme with SAM
binding first followed by C4-ACP binding and the ordered release of holo-ACP, C4-HSL,
and MTA (Figure 12). Therefore, RhlI reaction will follow equations 11 and 13 and the
1

double reciprocal plot of V vs

1
[SAM]

at various fixed [C4-ACP] would show both slope

and intercept-effects.

Figure 12.
Cleland diagram of RhlI catalyzed ordered bi-ter reaction. “E”
denotes free RhlI enzyme while “A,” “B,” “P,” “Q,” and “R” represents SAM, C4-ACP,
holo-ACP, C4-HSL, and MTA, respectively.
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However, to simplify the equation, if one of the substrates were to be at saturating
concentrations (e.g. [A]>>> [B], KmA), any term not including the [A] term would drop
out to form:
𝑉=

𝑉𝑚𝑎𝑥 [𝐴][𝐵]
𝐵 [𝐴]+[𝐴][𝐵]
𝐾𝑚

(15)

then the [A] term in the remaining equation would cancel out, simplifying the equation
to:
𝑉=

𝑉𝑚𝑎𝑥 [𝐵]
𝐵 +[𝐵]
𝐾𝑚

(16)

which is mathematically identical to the Michaelis-Menten equation. Therefore, by
keeping one substrate, “A”, at a saturating concentration and varying the concentration of
the other substrate, “B”, the apparent Km, Vmax, and kcat values of the enzyme associated
with “B” substrate can be determined, which will be referred to as “V vs [S]” kinetics. In
this study, substrate “A” corresponds to SAM and substrate “B” corresponds to C4-ACP
Enzyme Inhibition
Inhibitors can decrease enzyme activity in one of three ways: competitive
inhibition, uncompetitive inhibition, and mixed mode of inhibition (Figure 13). In
competitive mode of inhibition, the inhibitor is competing with the substrate for the same
enzyme form; in uncompetitive mode of inhibition, the inhibitor is not competing with
the substrate and binds to a different enzyme form; and in mixed mode of inhibition, the
inhibitor binds with both the same and different forms of the enzyme.
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Figure 13.
Modes of inhibition. (a) Competitive mode of inhibition: the inhibitor
competes with the substrate for the same enzyme form. (b) Uncompetitive mode of
inhibition: the inhibitor and the substrate bind to different enzyme form. (c) Mixed mode
of inhibition: the inhibitor binds to both the same and different enzyme forms.
Noncompetitive inhibition is a special case of mixed mode when the Ki and Kii values are
equal.
The mode of inhibition can be determined by conducting the V vs [S] kinetics
assay at different inhibitor concentration and the resulting rate curves will fit to the
following form of the Michaelis-Menten equation:
𝑎𝑝𝑝

𝑉=

𝑉𝑚𝑎𝑥 [𝑆]

𝑎𝑝𝑝
𝐾𝑚 +[𝑆]

(17)

If the inhibitor is targeting the same form of the enzyme to which the variable substrate
𝑎𝑝𝑝
binds, it would be inhibiting the enzyme competitively and mathematically, the 𝑉𝑚𝑎𝑥
and
𝑎𝑝𝑝
the 𝐾𝑚
would be:
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𝑎𝑝𝑝

𝑉𝑚𝑎𝑥 = 𝑉𝑚𝑎𝑥
𝑎𝑝𝑝

𝐾𝑚

= 𝐾𝑚 (1 +

(18)
[𝐼]
𝐾𝑖𝑠

)

(19)

𝑎𝑝𝑝
𝑎𝑝𝑝
since 𝐾𝑚
changes while 𝑉𝑚𝑎𝑥
remains unaffected, according to the Lineweaver-Burk

equation, the inhibition produces a slope-effect, denoted by Kis (binding affinity of the
inhibitor to E form). Mechanistically, as substrate concentration increases, Le Chatlier’s
principle predicts that the reaction would be pushed forward to form more EA complex,
which would decrease the concentration of free enzyme, E. The decrease in E
concentration would push the EI complex to revert to E + I. Therefore, the substrate can
outcompete the inhibitor at high concentrations (closer to the y-axis of the double
reciprocal plot) and reach Vmax (no intercept-effect). However, the interference in binding
increases the concentration of substrate for half-maximal rate (Km), thus increasing the
𝐾𝑚
𝑉𝑚𝑎𝑥

, or the slope (slope-effect). This inhibition pattern can be generalized to the

following observation: if the inhibitor binds with the same form of the enzyme, “E,” as
the variable substrate or binds with an enzyme form reversibly connected to “E” form,
there is slope-effect.
If the inhibitor is targeting a different form of the enzyme as the variable
𝑎𝑝𝑝
𝑎𝑝𝑝
substrate, it would be inhibiting the enzyme uncompetitively and the 𝑉𝑚𝑎𝑥
and the 𝐾𝑚

would be:
𝑎𝑝𝑝

𝑉𝑚𝑎𝑥 =
𝑎𝑝𝑝

𝐾𝑚

=

𝑉𝑚𝑎𝑥
[𝐼]
)
𝐾𝑖𝑖

(1+

𝐾𝑚
[𝐼]
)
𝐾𝑖𝑖

(1+

(20)

(21)

𝑎𝑝𝑝
since 𝑉𝑚𝑎𝑥
changes, the Lineweaver-Burk equation dictates that this inhibition would

cause an intercept-effect, denoted by Kii (binding affinity of the inhibitor to the ES form).
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[𝐼]

𝑎𝑝𝑝
𝑎𝑝𝑝
Moreover, as both the 𝐾𝑚
and the 𝑉𝑚𝑎𝑥
are changed by the same ratio, (1 + 𝐾 ), the
𝑖𝑖

𝐾𝑚

slope, 𝑉

𝑚𝑎𝑥

, remains the same. Mechanistically, since the inhibitor is binding to a

different enzyme form than the substrate binding to, increasing the substrate
concentration cannot overcome the inhibition; therefore, even at saturating substrate
concentration (near y-axis), the apparent Vmax is lower than true Vmax (intercept-effect).
As noted above, slope-effect is only observed if the inhibitor and the variable substrate
are binding to the same enzyme form or reversibly connected enzyme forms; in
uncompetitive inhibition, the inhibitor binds to a different form of the enzyme and no
slope-effect is observed. This inhibition pattern can be generalized as: if the inhibitor and
the variable substrate bind with different forms of the enzyme, there is intercept-effect.
If the inhibitor is targeting both the same and a different form of the enzyme as
the variable substrate, it would be inhibiting the enzyme via mixed model inhibition and
𝑎𝑝𝑝
𝑎𝑝𝑝
the 𝑉𝑚𝑎𝑥
and the 𝐾𝑚
would be:
𝑎𝑝𝑝

𝑉𝑚𝑎𝑥 =

𝑎𝑝𝑝
𝐾𝑚

=

𝑉𝑚𝑎𝑥
[𝐼]
)
𝐾𝑖𝑖

(1+

[𝐼]
)
𝐾𝑖𝑠
[𝐼]
(1+ )
𝐾𝑖𝑖

𝐾𝑚 (1+

(22)

(23)

𝑎𝑝𝑝
𝑎𝑝𝑝
since 𝐾𝑚
and 𝑉𝑚𝑎𝑥
change by differing ratios, the Lineweaver-Burk equation indicates

that the inhibition would cause both slope and intercept-effects, denoted by having both
Kis and Kii. In this case, since the inhibitor also binds with a different form of the enzyme,
Vmax is affected and there is intercept-effect. Since the inhibitor and the substrate are
binding to the same form of the enzyme, there is also slope-effect. In a special case of
mixed model inhibition, in which the inhibitor binds to two different enzyme forms
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𝑎𝑝𝑝

equally well, the Kii value would equal Kis value and the 𝐾𝑚

value would be equal to

the 𝐾𝑚 value and only the Vmax would be affected.
Once the V vs [S] assays in varying [I] is conducted, the data can be fitted to all
the models and the best fit can be determined by Akaike’s information criterion method
(AIC), which compares the scatter about the fit and the degrees of freedom associated
with each model and assay. In this model, the different inhibition models are listed in
order of increasing complexity in the following manner: competitive, noncompetitive,
uncompetitive, and mixed model. The AIC model compares two inhibition patterns at a
time, the simpler model (fewer parameters) assigned “model 1” and the more complex
model (more parameters) assigned “model 2,” with the following equation:
∆𝐴𝐼𝐶 = 𝑁 ∙ 𝑙𝑛

𝑆𝑆2
𝑆𝑆1

+ 2∆𝐷𝐹 = 𝐴𝐼𝐶1 − 𝐴𝐼𝐶2

(24)

in which SS1 and SS2 refers to sum of the square of the scatter about the fit in inhibition
models 1 and 2 and ΔDF, the difference in the degrees of freedom due to the parameters
associated with the inhibition models. The simpler model is expected to have bigger/more
𝑆𝑆2

scatter and higher degree of freedom; therefore, the ln 𝑆𝑆1 term is expected to be negative
and the ∆𝐷𝐹 term, positive. If the ∆𝐴𝐼𝐶 is negative, it would indicate that the scatter in
the simpler model 1 was greater than expected thus model 2 would be a better fit, and if
the ∆𝐴𝐼𝐶 is positive, the opposite would be true and model 1 would be a better fit. The
overall probability of one model being the better fit over the other is determined by the
following equation:
𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =

𝑒 0.5∙∆𝐴𝐼𝐶
1+𝑒 0.5∙∆𝐴𝐼𝐶

(25)

By repeating the AIC comparison between each of the inhibition models, the best fit can
be determined, thereby identifying the mode of inhibition.
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Although assaying the enzyme with various fixed inhibitor concentration and
variable substrate concentration is useful in determining the mode of inhibition and the
binding affinity of the inhibitor to the enzyme, it is a laborious and time-consuming
process. To quickly determine whether a compound is inhibiting, the enzyme is assayed
at fixed substrate concentration and variable inhibitor concentration. The kinetics data
from this test shows the potency of the inhibitor as the concentration of the inhibitor
required to reduce the enzyme initial rate by half, or the IC50 value; however, the IC50
value alone cannot be used to determine the mechanistic mode of inhibition or the
binding affinity of the inhibitor for the enzyme. The IC50 value can be calculated by the
following equation:
𝑉=

𝑉𝑚𝑎𝑥 −𝑉𝑚𝑖𝑛
[𝐼]ℎ
)
𝐼𝐶50ℎ

(26)

(1+

in which Vmax and Vmin refers to the starting and the minimum activities, respectively; [I],
the inhibitor concentration; and h, the hill constant (Figure 14).54

Figure 14.
Representative IC50 curve. The enzyme rate with no inhibitor is the
baseline, denoted Vmax. The concentration of the inhibitor required to reach half Vmax rate
is IC50.
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Under competitive mode of inhibition, the Ki and the IC50 values are related by:
𝐾𝑖 =

𝐼𝐶50
𝑆
)
𝐾𝑚

(1+

(27)

under uncompetitive mode:
𝐾𝑖 =

𝐼𝐶50
𝐾
(1+ 𝑚 )

(28)

𝑆

and under noncompetitive mode:
𝐾𝑖 = 𝐼𝐶50

(29)

However, if a compound were to bind at an allosteric site and alter the enzyme
structure to promote product release (increase kcat and maybe decrease Km) or substrate
binding (decrease Km), the enzymatic rate would increase. If the enzyme is assayed with
fixed concentration of the substrate and variable concentration of the agonist, EC50 is the
concentration of the activator at which the enzyme rate is half way between the baseline
and the maximum. and this agonistic effect would be modeled by the EC50 equation:
𝑉 = 𝑉𝑚𝑖𝑛 +

[𝐴]ℎ ∙(𝑉𝑚𝑎𝑥 −𝑉𝑚𝑖𝑛 )
([𝐴]ℎ +𝐸𝐶50ℎ )

(30)

where Vmin and Vmax refers to the starting and the maximum rates, respectively; [A], the
activator concentration; and h, the hill constant (Figure 15).55
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Figure 15.
Representative EC50 curve. The enzyme rate with no activator is the
baseline and the maximum enzyme rate reached with addition of the activator is denoted
Vmax. The concentration of the activator required to reach halfway between the baseline
and Vmax is EC50.
Thesis objective
The objective of this thesis is to determine how altering the acyl-chain, chirality,
and the head-group polarity of native AHL signal molecule changes the activity of RhlI
to determine the moieties of greatest important and understand the mechanism of their
effect.
The native AHL product, butanoyl-L-homoserine lactone, was used as the control.
The L-homoserine lactone headgroup alteration was the focus of the first generation of
AHL analogs (compounds 1-12; Table 2). Modifications to the lactone ring (compounds:
2-4, 8-12), the chirality (compounds: 5, 12), and the tail-headgroup linkage (compounds:
6, 7, 10-12). Variations in the acyl-chains were introduced in the next generation of AHL
analogs (Table 3) which was combined with the lessons learned from the first generation
of AHL derivative to target headgroup hydrophobicity with thiolactone, cyclopentyl, and
non-lactone compounds (compounds 8, 43-64, 76, 77; 4, 65-68; 2-3, 9-11, 69-73; 76-77;
Table 4, 5), D vs L headgroup chirality (compounds 5, 28-36; 12, 41-42; 56-64, 75, 77;
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Table 4), sulfonamide linkage (compounds 6, 37-40; 12, 41-42; Table 4), and acyl-chain
length and substitution at the C3 position (Compounds 13-55, 57-68, 70-73, 78-82; Table
4, 5). The acyl-chain effects were further correlated by testing RhlI activity with acylACP substrates of varying acyl-chain moieties (compounds 83-87; Table 4; Figure 16)
and testing the activity in the presence of alkyl-ACP (inactive acyl-ACP analogs;
compounds 88-91; Table 6; Figure 16). Finally, the importance of the ACP moiety in
binding was tested by observing RhlI activity in the presence of alkyl-CoAs (compounds
92-94; Table 4; Figure 16).
This is the first study to test the effects of modified AHLs on AHL synthases. The
work described in this thesis is the basis upon which future of rational inhibitor design
can be based.
Table 2.
Structures of 1st generation AHL-based small molecules tested for
RhlI inhibition.
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Table 3.
Variations in the acyl-chains for 2nd generation of AHL-based small
molecules tested for RhlI inhibition.
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2nd generation of AHL-based small molecules tested for RhlI

Table 4.
inhibition.a
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Table 5.

Nonlactone derivatives tested for RhlI inhibition
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Figure 16.
Structures of Acyl-ACP and CoA. (a) Apo-ACP is a relatively small
protein made up of four helices. When apo-ACP is linked with a pantetheine linker, it is
called holo-ACP. Acylated holo-ACPs are called acyl-ACPs. (b) Free coenzyme A
consists of a nucleotide connected to the pantetheine linker. Acylated CoAs are called
acyl-CoAs.
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CHAPTER TWO: MATERIALS AND METHODS
Materials and Equipment
The following reagents were purchased from Sigma Aldrich: (S)-(+)-αmethoxyphenylacetic acid (MPA), 2-(N-morpholino)ethanesulfonic acid hydrate (MES),
2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid), 2,6-dichloroindophenol (DCPIP),
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), ammonium sulfate, Dhomoserine lactone hydrochloride, DL-homocysteine thiolactone,
ethylenediaminetetraacetic acid (EDTA), glycerol, L-homoserine lactone hydrochloride,
magnesium sulfate anhydrous (MgSO4), maltose, N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide, Nα-tosyl-L-lysine
chloromethyl ketone hydrochloride (TLCK), phenylmethanesulfonyl fluoride (PMSF),
protamine sulfate, S-(5′-adenosyl)-L-methionine chloride (SAM), sucrose, toluene,
trichloroacetic acid, coenzyme A free acid (CoA-SH), butanoyl-coenzyme A (C4-CoA),
hexanoyl-coenzyme A (C6-CoA), octanoyl-coenzyme A (C8-CoA), decanoyl-coenzyme
A (C10-CoA), dodecanoyl-coenzyme A (C12-CoA), deoxyribonuclease I (DNase),
ribonuclease A (RNase), lysozyme, ampicillin, kanamycin, chloramphenicol, kanamycin,
spectinomycin, and streptomycin. Thermo Fisher Scientific supplied the following: 2propanol (IPA), acetonitrile, agar, ammonium acetate, bacterial protein extraction reagent
(B-PER), chloroform, diethyl ether, dimethylformamide (DMF), dimethyl sulfoxide
(DMSO), ethyl acetate, hydrochloric acid (HCl), imidazole, isopropyl β-D-1thiogalactopyranoside (IPTG), Lennox broth, manganese sulfate (MnSO4), methanol,
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hexane, potassium carbonate, silica, sodium bicarbonate, tricine, and tris base. Butyric
acid, hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid, and trifluoroacetic
acid (TFA) were obtained from Acros Organics. Alfa Aesar provided bromobutane,
bromohexane, bromooctane, bromodecane, magnesium chloride (MgCl2), and triethyl
amine. The 3kD and 10kD spin filter columns and celite were purchased from EMD.
Amylose resin, ethanol, and 0.22 µm sample filters were provided by NEB, Ultra Pure,
and Costar, respectively. Dr. Peter Tipton (University of Missouri, Columbia), Dr. E.
Peter Greenberg (University of Washington), and Dr. Michael Burkart (University of
California-San Diego) provided clones for purifying RhlI, apo-ACP, and Sfp,
respectively. Sfp was purified by Levi Mitchell and Nhu Lam (Both from Nagarajan lab,
Boise State University). Various AHL analogs were supplied by Dr. Helen Blackwell
(University of Wisconsin, Madison; compounds 1, 3-9, 12-55, 65-73), Dr. Eric Brown
(Boise State University; compounds 2, 10, 11), and Neil Rexrode (Nagarajan lab, Boise
State University; compounds 34, 36).
All UV-Vis spectrophotometric data was collected with Thermo Scientific
Evolution 260 Bio UV-Vis spectrophotometer using Fisher 1 cm path length quartz
cuvettes (14-385-928C). HPLC data was obtained with Thermo Scientific Dionex
UltiMate 3000 UHPLC+ focused HPLC with Dionex UltiMate 3000 Automated Fraction
Collector using Thermo Scientific Hypersil Gold C18 reverse-phase UHPLC column
(25002-054630) or Thermo Scientific Hypersil Gold C18 reverse-phase preparative
column (25005-159070). All mass spectrometry data was collected with Bruker maXis
Quadrupole Time-of-Flight (QTOF) mass spectrometry and analyzed with the Bruker
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Compass Data Analysis software. All the kinetics data were processed using GraphPad
Prism 7.
Methods
HPLC Methods
HPLC and the fraction collector was used to isolate and collect alkyl-CoA and to
monitor the synthesis and purity of acyl-ACP synthesis. Solvent “A” consisted of 25 mM
ammonium acetate pH 5 solution. Solvent “B” is acetonitrile (ACN) + 0.1%
trifluoroacetic acid (TFA), and solvent “C” is H2O + 0.1% TFA. To isolated alkyl-CoA,
the filtered sample was injected into a C18 reverse-phase preparatory column equilibrated
with the initial solvent condition of 95.0% solvent A and 5.0% solvent B. The analyte
was analyzed using a solvent gradient of 95.0% solvent A and 5.0% solvent B to 30.0%
solvent A and 70.0% solvent B over 11 minutes at a flow rate of 3.0 mL/min (Table 7).
To monitor acyl-ACP synthesis, the analyte sample was injected into a C18 reverse-phase
UHPLC column equilibrated with 25.0% solvent B and 75.0% solvent C. The acyl-ACP
peaks were separated from apo-ACP peak with a solvent gradient of 25.0% solvent B and
75.0% solvent C to 75.0% solvent B and 25.0% solvent C over 10 minutes at a flow rate
of 600 µL/min (Table 8). Due to the similar retention time for hexanoyl/hexyl-ACP and
apo-ACP, a shallower gradient of 25.0% solvent B and 75.0% solvent C to 75.0% solvent
B and 25.0% solvent C over 60 minutes at a flow rate of 200 µL/min was used (Table 9).
The column and the sample loop were washed with methanol for 5 minutes between each
run.
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Table 7.

Alkyl-CoA separation methoda

Flow
%Ab
(mL/min)
-3.00
3.000
95.0
0.00d
3.000
95.0
1.00
3.000
95.0
11.00
3.000
30.0
a = Preparatory column
b = 25 mM ammonium acetate pH 5
c = acetonitrile (ACN) + 0.1% trifluoroacetic acid (TFA)
d = sample injection at Time 0.00
Time (min)

Table 8.

5.0
5.0
5.0
70.0

ACP separation methoda
Flow
(mL/min)
0.600
0.600
0.600

Time (min)

-3.00
0.00d
10.00
a = UHPLC column
b = ACN + 0.1% TFA
c = H2O + 0.1% TFA
d = sample injection at Time 0.00

Table 9.

%Bc

%Bb

%Cc

25.0
25.0
75.0

75.0
75.0
25.0

C6-ACP separation methoda

Time (min)

Flow
(mL/min)
0.200
0.200
0.200

-3.00
0.00d
60.00
a = UHPLC column
b = ACN + 0.1% TFA
c = H2O + 0.1% TFA
d = sample injection at time 0.00

%Bb

%Cc

25.0
25.0
75.0

75.0
75.0
25.0

RhlI Purification
RhlI was purified via a previously described method with modifications.52 E. coli
with RhlI plasmid was grown on an agar plate (20 g Lennox broth and 10 g agar per 1 L
of medium) with ampicillin (100 µg/mL) for 12 hours at 37°C. A colony was isolated and
was used to inoculate 25 mL of Lennox broth with ampicillin (100 µg/mL) and incubated
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at 37°C with shaking (225 rpm) for 8-12 hours or until visible turbidity. The “minigrowth” was then transferred over to 1 L of Lennox broth (20 g broth/L) with ampicillin
(100 µg/mL). The broth was incubated with shaking (225 rpm) at 37°C. When the OD600
value reached 0.6-0.8, IPTG was added to 0.5 mM final concentration to promote protein
expression. The cell culture was incubated for 3 hours at room temperature. The growth
media was then spun down at 5,000 x g at 4°C for 15 minutes to collect cell paste. The
cell pellet was resuspended in “Buffer A,” which is composed of 200 mL of 50 mM TrisHCl, pH 7.5, containing 0.2 M NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.1
mM phenylmethanesulfonyl fluoride (PMSF), 0.1 mM Nα-tosyl-L-lysine chloromethyl
ketone hydrochloride (TLCK), 0.4 M sucrose, and 2.5% (v/v) glycerol. The resuspended
mixture was then lysed via sonication at 15,000 psi. The lysate was spun down for 40
minutes at 10,000 x g and at 4°C. Protamine sulfate was added to the supernatant to a
final concentration of 6 mg/ g of cell pellet to cause nucleic acids to precipitate. The
nucleic acid precipitates were removed via centrifugation for 20 minutes at 10,000 x g
and at 4°C. The supernatant was then loaded onto an amylose column that has been
equilibrated with 5x bed volume with buffer A. The column was washed with 5x bed
volume with buffer A. RhlI was eluted out using buffer A with 10 mM maltose added.
The presence and purity of RhlI was checked with SDS-PAGE gel electrophoresis. The
protein sample was concentrated using 10 kD spin filter, the concentration checked via
UV-Vis spectrophotometry (ε280= 107510 M-1cm-1), and stored in buffer A with 20%
glycerol at -80 °C.
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Apo-ACP Purification
Apo-ACP was purified with a well-established method.22 E. coli DK574 with
pjT94 was grown on an agar plate (20 g Lennox broth and 10 g agar per 1 L of medium)
with kanamycin (25 µg/mL), streptomycin (50 µg /mL), spectinomycin (50 µg /mL), and
chloramphenicol (25 µg /mL) for 12 hours at 37°C. An isolated colony was used to
inoculate 25 mL of Lennox broth with kanamycin (25 µg/mL), streptomycin (50 µg
/mL), spectinomycin (50 µg /mL), and chloramphenicol (25 µg /mL) and incubated at
37°C with shaking (225 rpm) for 8-12 hours or until visible turbidity. The “mini-growth”
was then transferred over to 1 L of Lennox broth (20 g broth/L) with kanamycin (25
µg/mL), streptomycin (50 µg /mL), spectinomycin (50 µg /mL), and chloramphenicol (25
µg /mL) and incubated at 37°C with stirring until OD600 value reached 0.6-0.8. IPTG was
then added to a final concentration of 1 mM to promote protein expression. The cell
culture was incubated at 37°C for a further 3 hours then collected via centrifugation at
5,000 x g for 15 minutes. The cell paste was resuspended in 2 mL of B-PER reagent, 1
mL of lysozyme (2 mg/mL) 20 μL each of DNase (1 mg/mL) and RNase (1 mg/mL) and
25 μL of phenylmethylsulfonyl fluoride (13 mg/750 μL 2-propanol) to lyse the cells and
their nucleic acids. The lysate mixture was incubated with gentle shaking at room
temperature for 20 minutes. The lysate was spun down for 30 minutes at 20,000 x g and
at 4°C. The supernatant was collected and was added MgCl2 and MnSO4 to final
concentrations of 25 mM and 1.2 mM, respectively and incubated at 37°C for 4 hours.
Extraneous proteins were precipitated by slow addition of 2-propanol to 50% initial
volume while on ice. The precipitates were removed via centrifugation at 14,000 x g for
30 minutes. The supernatant was stirred with 2 g of DE52 diaminoethyl cellulose resin
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overnight at 4°C. The mixture was packed in to a column and washed with 10 x bed
volume with 10 mM lithium 4-morpholineethane-sulfonate (MES) pH 6.1 and 0.25 mM
LiCl. The protein was eluted out using 10 mM lithium MES pH 6.1 and 0.5 M LiCl. The
presence and purity of apo-ACP was checked via Tris/Tricine SDS-PAGE gel
electrophoresis. Apo-ACP samples were polled and the protein was precipitated with the
addition of 0.02% (0.2 mg/mL) sodium deoxycholate and 5% (50 mg/mL)
trichloroacetate (w/v). The mixture was incubated at 37°C with gentle shaking for 30
minutes. The mixture was then spun at 21,000 x g for 30 minutes to collect ACP pellet.
The ACP pellet was resuspended in 60 mL of 0.5 M Tris-HCl pH 8.0 and concentrated
using 3 kD spin filter. The concentration was determined via UV-Vis spectrophotometry
(ε280= 1490 M-1cm-1), and stored in 10 mM MES pH 6.1 + 20 % glycerol at -80 °C.
Alkyl-CoA Synthesis
To a solution of coenzyme A, free acid (CoA-SH; 50 mg, 65.1 µmol) and alkyl
bromide (120.2 µmol) in 2mL of 1:1 water:DMF, potassium carbonate was added to pH
8-9 (Figure 17). The reaction was stirred under nitrogen overnight and the completion of
the reaction was tested by checking for the reduction of DCPIP by unreacted CoA-SH.
The reaction mixture was diluted with water to a final volume of 5 mL and extracted with
5 mL of diethyl ether. The aqueous mixture was filtered with 0.2 µm filter and the alkylCoA was isolated and collected with semi-prep HPLC using the Alkyl-CoA separation
method (Table 5). Organic solvent was removed via evaporation by a gentle stream of
nitrogen through the product solution and the aqueous solution was lyophilized to yield
alkyl-CoA powder.
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Figure 17.
Synthesis of alkyl-CoA. Alkyl bromide was reacted with free-CoA in
basic solution to produce alkyl-CoA.
92. Butyl-Coenzyme A. ESI-TOF: expected m/z [M + H+] = 824.1851,
observed [M + H+] = 824.1835. (Appendix Figures A14)
93. Hexyl-Coenzyme A. ESI-TOF: expected m/z [M + H+] = 852.2164,
observed [M + H+] = 852.2147. (Appendix Figures A15)
94. Octyl-Coenzyme A. ESI-TOF: expected m/z [M + H+] = 880.2477,
observed [M + H+] = 880.2444. (Appendix Figures A16)
95. Decyl-Coenzyme A. ESI-TOF: expected m/z [M + H+] = 908.2790,
observed [M + H+] = 908.2733. (Appendix Figures A17)
Alkyl-/Acyl-ACP synthesis
Alkyl-/acyl-pantetheine was transferred from CoA to apo-ACP via
phosphopanetheinyl transferase (Sfp) catalyzed reaction (Figure 18).22 The reaction
mixture consisted of 50 mM Tris-HCl pH 6.8, 10 mM magnesium chloride, 600 µM apoACP, 750 µM alkyl-/acyl-CoA, and 10 µM Sfp, with the CoA-substrate being the last to
be added. Alkyl-/acyl-CoAs with aliphatic chains of 6 and fewer carbons were added all
at once. Alkyl-/acyl-CoAs with aliphatic chains of 8 or more carbons were added in three
equal portions every 15 minutes to prevent CoA precipitating and crashing out of the
pridominantly aqueous reaction mixture. The reaction was incubated at 37 °C and
checked via HPLC every 30 minutes for completion using ACP separation method (Table
6). However, C6-ACP separation method was used to check hexyl- and hexanoyl-ACP
synthesis since C6-ACP, C6-IACP, and apo-ACP have similar retention time (Table 7).
For completion, reactions lasted 2 hours for C4-ACP and C4-IACP, between 4 and 5
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hours for C6-ACP and C6-IACP, and 6 to 7 hours for C8- to C12-ACP and IACPs. Upon
completion, ammonium sulfate was added to the reaction to 75% saturation and kept at 4
°C for 1 hour to precipitate Sfp.56 The Sfp precipitates were pelleted by centrifugation at
15,000 x g for 15 minutes. The supernatant was desalted and concentrated by 3 kD spin
filter spun at 5,000 x g at 4 °C. The concentration was determined via UV-Vis
spectrophotometry (ε280= 1490 M-1cm-1), and stored in 10 mM MES pH 6.1 + 20 %
glycerol at -80 °C.

Figure 18.
Sfp catalyzed acyl-pantetheine transfer reaction. Sfp catalyzes the
transfer of pantetheine linker from a CoA to apo-ACP to produce alkyl-/acyl-ACP.
83-87. Butanoyl-, Hexanoyl-, Octanoyl-, Decanoyl-, and Dodecanoyl-ACP. Mass
confirmed in previous work from Nagarajan laboratory.22
88. Butyl-ACP. ESI-TOF: expected mass = 8904.6, observed mass = 8904.3.
(Appendix Figures A10)
89. Hexyl-ACP. ESI-TOF: expected mass = 8932.6, observed mass = 8932.4.
(Appendix Figures A11)
90. Octyl-ACP. ESI-TOF: expected mass = 8960.7, observed mass = 8960.4.
(Appendix Figures A12)
91. Decyl-ACP. ESI-TOF: expected mass = 8988.7, observed mass = 8988.4.
(Appendix Figures A13)
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Purification of D-homocysteine thiolactone
Enantiomerically pure sample of D-homocysteine thiolactone was obtained using
a published method with modification (Figure 19).57 A solution of DL-homocysteine
thiolactone (768.15 mg; 5.0 mmole), triethylamine (N(Et)3; 1.2 mL), Nhydroxysuccinimide (690.5 mg; 6 mmole), S-(+)-2-methoxyphenylacetic acid (MPA; 1.0
g; 6.0 mmole), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl (EDC; 1.150 g;
6 mmole) in 100 mL chloroform was stirred overnight at 4°C. This reaction resulted in
the synthesis of L-homocysteine thiolactone-containing (3S,2′S)-3-(2′-methoxy-2′phenyl-)acetamido-2-thiophenone and D-homocysteine thiolactone-containing (3R,2′S)3-(2′-methoxy-2′-phenyl-)acetamido-2-thiophenone. The solution was then washed with
water (50 mL), NaHCO3 (5%, 20 mL), HCl (2M, 20 mL), and brine (saturated, 40 mL).
After drying with MgSO4, the solvent was removed under low pressure. The two
diastereomers were separated by silica gel column chromatography using hexane-ethyl
acetate solution (7:3). The more polar, D-thiolactone-containing isomers were isolated
and refluxed in ethanol-4M HCl (2:1; 15 mL) solution overnight. Ethanol was removed
with rotary evaporation. Water was added to the resulting solution to make it 10 mL and
washed with toluene (10 mL x 3). The aqueous layer was isolated and the solvent was
removed under high vacuum. The resulting D-thiolactone-HCl mixture was recrystallized
with anhydrous 2-propanol.
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Figure 19.
Purification of pure D-homocysteine thiolactone. A racemic mixture
was acylated with MPA in an EDC-coupled reaction to form diastereomers with distinct
polarity. The two diastereomers separated via silica gel column chromatography. DHomocysteine thiolactone was obtained by removing the MPA by refluxing the
compound in HCl.
D-Homocysteine thiolactone HCl. (comparable to literature value57) m.p. 176-178°C
1
[𝛼]25
𝐷 -36.3 (0.05 mg/mL in H2O). H NMR (600 MHz, D2O): δ 2.10 (1H, m, 4α-H), 2.62

(1H, m, 4β-H), 3.33 (1H, m, 5α-H), 3.24 (1H, m, 5β-H), 4.29 (1H, s, 3-H). (Appendix
Figure B1)
Synthesis of N-acyl-D-homocysteine thiolactones
The D-thiolactone head-group was acylated using a previously published protocol
with modification (Figure 20).43 The thiolactone head-group (25 mg; 162.7 µmole) was
stirred overnight (12 hours) at room temperature with DCC (33.6 mg; 162.7 µmole), Nhydroxysuccinimide (18.7 mg; 162.7 µmole), triethylamine (50 µL) in acetonitrile (10
mL) with the appropriate carboxylic acid (162.7 µmole: butyric acid: 14.9 µL; hexanoic
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acid: 20.6 µL; octanoic acid: 25.8 µL; decanoic acid: 28 mg; dodecanoic acid: 32.6 mg).
The resulting mixture was cooled to 4 °C for an hour and then filtered with celite to
remove N,N′-dicyclohexylurea precipitate. The filtrate solution was washed with water,
HCl (2M), NaHCO3 (saturated), and brine (saturated) (3x10 mL each). After drying with
MgSO4, and removing the solvent under low pressure, the product was purified with a
silica gel column using 7:3 hexane: ethyl acetate eluent.

Figure 20.
Acylation of D-thiolactone headgroup. D-thiolactone headgroup was
acylated by a DCC-coupled reaction in acetonitrile. Urea byproduct was removed via
filtration and excess carboxylic acid was removed via silica gel column chromatography.
56. N-Butanoyl-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ 0.93 (3H,
t, J = 7.3 Hz, CH3), 1.65 (2H, m, CH2), 1.90 (1H, m, -lac), 2.20, (2H, dt, J = 7.3, 3.9 Hz,
CH2), 2.93 (1H, m, -lac), 3.23 (1H, ddd, J = 11.4, 4.5, 1.0 Hz, -lac), 3.33 (1H, ddd, J =
11.7, 11.7, 5.1 Hz, -lac), 4.49 (1H, ddd, J = 12.9, 6.4, 6.4 Hz, -lac), 5.92 (1H, s, NH); 13C
NMR (CDCl3, 600 MHz): δ 13.9, 19.2, 27.8, 32.4, 38.5, 59.7, 173.7, 205.8; ESI-TOF:
expected m/z [M + H+] = 188.0734, observed [M + H+] = 188.0763. (Appendix Figures
A1, B2-B6)
57. N-Hexanoyl-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ 0.87 (3H,
t, CH3), 1.29 (4H, m CH2), 1.64 (2H, m, CH2), 1.89 (1H, m, -lac), 2.22, (2H, dt, J = 7.5,
3.5 Hz, CH2), 2.97 (1H, m, -lac), 3.24 (1H, ddd, J = 11.4, 6.9, 1.1 Hz, -lac), 3.34 (1H,
ddd, J = 11.7, 11.7, 5.3 Hz, -lac), 4.48 (1H, ddd, J = 12.8, 6.4, 6.4 Hz, -lac), 5.83 (1H, s,
NH); 13C NMR (CDCl3, 600 MHz): δ 13.9, 22.4, 25.2, 27.6, 31.4, 32.2, 36.4, 59.6,
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173.7, 205.6; ESI-TOF: expected m/z [M + H+] = 216.1047, observed [M + H+] =
216.1099. (Appendix Figures A2, B7-B9)
58. N-Octanoyl-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ 0.86 (3H,
t, J = 6.9 Hz, CH3), 1.26 (8H, m CH2), 1.62 (2H, m, CH2), 1.88 (1H, m, -lac), 2.22, (2H,
dt, J = 7.5, 3.5 Hz, CH2), 2.96 (1H, m, -lac), 3.23 (1H, ddd, J = 11.3, 4.4, 0.9 Hz, -lac),
3.34 (1H, ddd, J = 11.7, 11.7, 5.2 Hz, -lac), 4.48 (1H, ddd, J = 12.9, 6.4, 6.4 Hz, -lac),
5.82 (1H, s, NH); 13C NMR (CDCl3, 600 MHz): δ 14.3, 22.8, 25.7, 27.8, 29.4, 29.9, 31.9,
32.5, 36.7, 59.8, 173.9, 205.8; ESI-TOF: expected m/z [M + H+] = 244.1360, observed
[M + H+] = 244.1405. (Appendix Figures A3, B10-B14)
59. N-Decanoyl-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ 0.85 (3H,
t, J = 6.9 Hz, CH3), 1.25 (12H, m CH2), 1.61 (2H, m, CH2), 1.87(1H, m, -lac), 2.21, (2H,
dt, J = 7.4, 3.6 Hz, CH2), 2.95 (1H, m, -lac), 3.23 (1H, ddd, J = 11.4, 4.5, 1.1 Hz, -lac),
3.34 (1H, ddd, J = 11.5, 11.5, 5.1 Hz, -lac), 4.48 (1H, ddd, J = 12.7, 6.3, 6.3 Hz, -lac),
5.86 (1H, s, NH); 13C NMR (CDCl3, 600 MHz): δ 14.0, 22.6, 25.5, 27.6, 29.2, 29.3, 29.4,
31.8, 32.2, 33.9, 36.4, 59.5, 173.6, 205.5; ESI-TOF: expected m/z [M + H+] = 272.1673,
observed [M + H+] = 272.1720. (Appendix Figures A4, B15-B19)
60. N-Dodecanoyl-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ 0.86
(3H, t, J = 6.8 Hz, CH3), 1.25 (16H, m CH2), 1.62 (2H, m, CH2), 1.88(1H, m, -lac), 2.21,
(2H, dt, J = 7.5, 3.4 Hz, CH2), 2.97 (1H, m, -lac), 3.23 (1H, ddd, J = 11.2, 4.4, 0.8 Hz, lac), 3.34 (1H, ddd, J = 11.7, 11.7, 5.3 Hz, -lac), 4.47 (1H, ddd, J = 12.8, 6.2, 6.2 Hz, lac), 5.81 (1H, s, NH); 13C NMR (CDCl3, 600 MHz): δ 14.1, 22.6, 24.9, 25.5, 27.6, 29.2,
29.3, 29.4, 29.6, 31.9, 32.2, 33.9, 36.4, 59.6, 173.6, 205.5; ESI-TOF: expected m/z [M +
H+] = 300.1986, observed [M + H+] = 300.2042. (Appendix Figures A5, B20-B24)
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Synthesis of N-(3-Oxoacyl)-D-homocysteine thiolactones
The synthesis of N-(3-oxoacyl)-D-homocysteine thiolactones has been developed
previously (Figure 21).58 A solution of Meldrum’s acid (300.0 mg; 2.1 mmole), DCC
(515.4 mg; 2.5 mmole), 4-(dimethylamino)pyridine (279.7 mg; 2.3 mmole), and the
appropriate carboxylic acid (2.1 mmole: butyric acid: 191.0 µL; hexanoic acid: 262.8
µL; octanoic acid: 329.9 µL; decanoic acid: 358.6 mg) in dichloromethane (10 mL) was
stirred at room temperature overnight. The resulting mixture was cooled to 4 °C for an
hour and then filtered with celite to remove N,N′-dicyclohexylurea precipitate. The
filtrate was washed with HCl (2M, 20 mL). After drying with MgSO4, the solvent was
removed under low pressure. A solution of D-homocysteine thiolactone HCl (30.0 mg;
0.2 mmole), triethylamine (35 µL) and the appropriate acylated Meldrum’s acid (0.2
mmole) in acetonitrile (10 mL) was prepared. The solution was stirred at room
temperature for 1 hour and then refluxed overnight. The solvent was removed under low
pressure and the product was then dissolved in ethyl acetate (10 mL). The solution was
washed with NaHCO3 (saturated), KHSO4 (1M), and brine (saturated) (10 mL x 3 each).
After drying with MgSO4, and removing the solvent under low pressure, the product was
purified with a silica gel column using 7:3 hexane: ethyl acetate eluent.
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Figure 21.
Synthesis and purification of 3oxoacyl-D-thiolactones. Carboxylic acid
was attached to Meldrum’s acid via DCC-coupled reaction. The acylated Meldrum’s acid
was reacted with thiolactone headgroup under heat. This reaction produced 3oxoacylthiolactone product and small amounts of a side product, which was removed via silica
gel column chromatography.
61. N-(3-Oxohexanoyl)-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ
0.91 (3H, t, J = 7.4 Hz, CH3), 1.61 (2H, m, CH2), 1.99 (1H, m, -lac), 2.49, (2H, t, J = 7.4
Hz, CH2), 2.83 (1H, m, -lac), 3.24 (1H, ddd, J = 11.5, 6.9, 1.0 Hz, -lac), 3.33 (1H, ddd, J
= 11.7, 11.7, 5.2 Hz, -lac), 3.43 (2H, s, CH2) 4.56 (1H, ddd, J = 12.9, 6.8, 6.8 Hz, -lac),
7.43 (1H, s, NH); 13C NMR (CDCl3, 600 MHz): δ 13.7, 17.1, 27.7, 31.8, 46.0, 48.6, 59.5,
166.4, 204.7, 206.6; ESI-TOF: expected m/z [M + H+] = 230.0845, observed [M + H+] =
230.0896. (Appendix Figures A6, B25-B29)
62. N-(3-Oxooctanyol)-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ
0.86 (3H, t, J = 7.1 Hz, CH3), 1.26 (4H, m CH2), 1.56 (2H, m, CH2), 1.99 (1H, m, -lac),
2.50, (2H, t, J =7.4 Hz, CH2), 2.82 (1H, m, -lac), 3.23 (1H, ddd, J = 11.4, 7.0, 1.1 Hz, lac), 3.33 (1H, ddd, J = 11.7, 11.7, 5.2 Hz, -lac), 3.43 (2H, s, CH2), 4.56 (1H, ddd, J =
13.0, 6.6, 6.6 Hz, -lac), 7.45 (1H, s, NH); 13C NMR (CDCl3, 600 MHz): δ 14.0, 22.6,
23.3, 27.7, 31.3, 31.7, 44.1, 48.6, 59.5, 166.4, 204.7, 206.7; ESI-TOF: expected m/z [M
+ H+] = 244.1360, observed [M + H+] = 244.1433. (Appendix Figures A7, B30-B34)
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63. N-(3-Oxodecanoyl)-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ
0.84 (3H, t, J = 7.1 Hz, CH3), 1.24 (8H, m CH2), 1.55 (2H, m, CH2), 1.99 (1H, m, -lac),
2.49, (2H, t, J = 7.4 Hz, CH2), 2.81 (1H, m, -lac), 3.23 (1H, ddd, J = 11.4, 7.1, 1.0 Hz, lac), 3.32 (1H, ddd, J = 11.8, 11.8, 5.3 Hz, -lac), 3.42 (2H, s, CH2), 4.56 (1H, ddd, J =
12.9, 6.6, 6.6 Hz, -lac), 7.46 (1H, s, NH); 13C NMR (CDCl3, 600 MHz): δ 14.2, 22.8,
23.6, 27.7, 29.14, 29.17, 31.7, 31.8, 44.0, 48.6, 59.4, 166.5, 204.7, 206.6; ESI-TOF:
expected m/z [M + H+] = 286.1471, observed [M + H+] = 286.1472. (Appendix Figures
A8, B35-B39)
64. N-(3-Oxododecanoyl)-D-homocysteine thiolactone. 1H NMR (600 MHz, CDCl3): δ
0.85 (3H, t, J = 7.1 Hz, CH3), 1.24 (12H, m CH2), 1.56 (2H, m, CH2), 1.99 (1H, m, -lac),
2.50, (2H, t, J = 7.3 Hz, CH2), 2.83 (1H, m, -lac), 3.24 (1H, ddd, J = 11.2, 6.9, 1.0 Hz, lac), 3.33 (1H, ddd, J = 11.7, 11.7, 5.2 Hz, -lac), 3.43 (2H, s, CH2), 4.56 (1H, ddd, J =
12.9, 6.7, 6.7 Hz, -lac), 7.45 (1H, s, NH); 13C NMR (CDCl3, 600 MHz): δ 14.3, 22.9,
23.6, 27.7, 29.2, 29.4, 29.5, 29.6, 31.8, 32.1, 44.1, 48.5, 59.4, 166.4, 204.7, 206.7; ESITOF: expected m/z [M + H+] = 314.1784, observed [M + H+] = 314.1791. (Appendix
Figures A9, B40-B14)
Mass Spectrometry
Molecular mass of ACP derivatives was determined by high performance liquid
chromatography mass spectrometry (HPLC-MS) using a high resolution Quadrupole
Time of Flight (QTOF) instrument with electrospray ionization (ESI). The ESI source
was operated at positive ion mode, the nebulizer pressure at 1.2 bar, nitrogen drying gas
flow at 8 L/min, drying temperature at 200 °C, and the voltage of the capillary and the
end-plate offset to 3000 V to -500 V. The mass range was set from 250 to 2900 m/z and
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low concentration ESI tuning mix (Agilent Technologies, Santa Clara, California) was
used to calibrate the instrument in the mass range. Ten microliters of samples were
injected onto a Phenomenex Kinetex XB-C18 column (100 x 2.1 mm, 2.6μm)
(Phenomenex Corporation, Torrance, California) at a flow rate of 0.3 mL/min followed
by a simple linear gradient for sample desalting and separation. The initial eluent was
98% mobile phase A (99.9% water, 0.1% formic acid) and 2% B (99.9% acetonitrile,
0.1% formic acid) for 5 min and then mobile phase B was increased to 50% in 25 min.
LC eluent was diverted to the waste during the first five minutes of the gradient to
eliminate salts in the sample buffer.
Small molecule samples were prepared in concentrations of 0.5 mg/mL in
methanol. Molecular mass of AHL analogs were determined with the instrument
described above with direct sample injection via ESI inlet. The ESI source was operated
at positive ion mode, the nebulizer pressure at 0.4 bar, nitrogen drying gas flow at 4
L/min, drying temperature at 200 °C, and the voltage of the capillary and the end-plate
offset to 3000 V to -500 V. The mass range was set from 80 to 800 m/z and sodium
formate was used to calibrate the instrument in this mass range.
The collected data was analyzed with the Bruker Compass Data Analysis software
and the observed m/z values were compared to the theoretical monoisotopic mass
calculated by Bruker Compass IsotopePattern software.
Kinetics Assays
Determination of Background rate
A colorimetric DCPIP indirect assay was used to determine RhlI activity.53 Assay
mixtures composed of HEPES buffer (100 mM, pH 7.3), SAM (300 µM), butanoyl-ACP
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(30 µM), DCPIP (30 µM), and sufficient nanopure water for a total volume of 100 µL
were tested, with DCPIP being added the last. Upon the addition of DCPIP, the
absorbance of the mixture was observed at 600 nm for 30 minutes. The background rate
was calculated by DCPIP reduction (ε600=21,000 M-1cm-1; see Chapter 1, equations 1-3).
The time range at which the background rate was 5% of the lowest enzyme rate observed
was used as the incubation time.
Determination of Kinetic Constants
Butanoyl- (C4), hexanoyl- (C6), octanoyl- (C8), decanoyl- (C10), and
dodecanoyl- (C12) ACPs were tested (compounds 83-87; chapter 1, Table 3). The
reaction mixture was composed of RhlI (0.3 µM or 0.9 µM), DCPIP (300 µM), SAM
(300 µM), HEPES buffer (100 mM, pH 7.3), varying concentrations of acyl-ACP (2-200
µM), and nanopure water for a total of 100 µL reaction volume. The RhlI concentration
was maintained at 0.3 µM when working with C4-ACP native substrate and kept to 0.9
µM when non-native substrates were tested. All components, sans enzyme, were
incubated together for 10 minutes prior to initiation by RhlI. The absorbance was
monitored for 300 seconds at 600 nm. The decrease in DCPIP absorbance in the 100 to
200 second range was converted to RhlI rate (equations 1-3, chapter 1) and fitted to
Michaelis-Menten equation (equation 5, chapter 1) to determine the kinetic constants.
Each run was conducted in triplicates and the spread used to determine error with
GraphPad Prism 7.
IC50/EC50 determination
Since AHLs are mostly hydrophobic, AHL derivatives were first dissolved in
DMSO. The IC50 value of DMSO was determined to identify the appropriate volume of
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DMSO to use. The reaction mixture was composed of RhlI (0.3 µM), DCPIP (300 µM),
SAM (300 µM), C4-ACP (14 µM), HEPES buffer (100 mM, pH 7.3), varying
concentrations of DMSO (10% – 25% total volume), and nanopure water for a total of
100 µL reaction volume. All components, sans enzyme, were incubated together for 10
minutes prior to initiation by RhlI. After enzyme addition, the absorbance was monitored
for 300 seconds at 600 nm. The decrease in DCPIP absorbance in the 100 to 200 second
range was converted to enzyme rate (equations 1-3, chapter 1) to determine the
appropriate volume of DMSO to use for RhlI enzyme assay.
The effects of various AHL analogs were tested by measuring their IC50 or EC50
values via DCPIP colorimetric assay. The reaction mixture was composed of RhlI (0.3
µM), DCPIP (300 µM), SAM (300 µM), C4-ACP (14 µM), HEPES buffer (100 mM, pH
7.3), varying concentrations (0 -2 mM) of AHL analogs in DMSO (10% of total reaction
volume as determined by above experiment; see Appendix Figure C17), and nanopure
water for a total of 100 µL reaction volume. All components, sans enzyme, were
incubated together for 10 minutes prior to initiation by RhlI. After enzyme addition, the
absorbance was monitored for 300 seconds at 600 nm. The decrease in DCPIP
absorbance in the 100 to 200 second range was converted to RhlI rate (equations 1-3,
chapter 1) and fitted to IC50 or EC50 equations depending on the effect (equations 26 and
30, chapter 1). Each run was conducted in triplicates and the spread used to determine
error with GraphPad Prism 7.
The effects of IACPs and ICoAs were tested by measuring their IC50 values via
DCPIP colorimetric assay. The reaction mixture was composed of RhlI (0.3 µM), DCPIP
(300 µM), SAM (300 µM), C4-ACP (14 µM), HEPES buffer (100 mM, pH 7.3), varying
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concentrations (0 - 1 mM) of IACP or ICoA, and nanopure water for a total of 100 µL
reaction volume. All components, sans enzyme, were incubated together for 10 minutes
prior to initiation by RhlI. After enzyme addition, the absorbance was monitored for 300
seconds at 600 nm. The decrease in DCPIP absorbance in the 100 to 200 second range
was converted to RhlI rate (equations 1-3, chapter 1) and fitted to IC50 equation (equation
26, chapter 1) with GraphPad Prism 7.
Time-dependent IC50 test
The inhibitory effects as a function of time was determined by incubating RhlI
with varying concentration of an inhibitor for 0, 10, 30, and 60 minutes. The reaction
mixture was composed of RhlI (0.3 µM), DCPIP (300 µM), SAM (300 µM), C4-ACP
(14 µM), HEPES buffer (100 mM, pH 7.3), varying concentrations (10 µM -2 mM) of
the inhibitor. All components, sans RhlI and the inhibitor, were incubated together for 10
minutes prior to initiation by RhlI-inhibitor mixture. Upon reaction initiation, the
absorbance was monitored for 300 seconds at 600 nm. The decrease in DCPIP
absorbance in the 100 to 200 second range was converted to RhlI rate (equations 1-3,
chapter 1) and fitted to IC50 or EC50 equations depending on the effect (equations 26 and
30, chapter 1). Each run was conducted in triplicates and the spread used to determine
error with GraphPad Prism 7.
Mode of Inhibition tests
The activity of RhlI as a function of C4-ACP concentration was determined under
varying amounts of an inhibitor. The inhibitor concentration was determined from the
IC50 test, choosing two concentrations below, two above and one run with zero inhibitor.
Each reaction mixture contained RhlI (0.3 µM), DCPIP (300 µM), SAM (300 µM),
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HEPES buffer (100 mM, pH 7.3), and varying concentrations of C4-ACP (2-20 µM) and
of the inhibitor (0-400 µM). The concentration of C4-ACP was varied while the inhibitor
concentration constant. All components, sans enzyme, were incubated together for 10
minutes prior to initiation by RhlI. The absorbance was monitored for 300 seconds at 600
nm. The decrease in DCPIP absorbance in the 100 to 200 second range was converted to
RhlI rate (equations 1-3, chapter 1) and fitted to modified Michaelis-Menten equation
using Vmaxapp and Kmapp to determine the apparent kinetic constants (equation 17, chapter
1). After determining the mode of inhibition, the Vmaxapp and Kmapp values were used to
calculate the inhibitor binding affinity, Ki, value (competitive mode of inhibition:
equations 18, 19; uncompetitive mode of inhibition: equations 20, 21; and mixed or
noncompetitive mode of inhibition: equations 22, 23; see chapter 1). Each data point was
collected in single run and fitted to various inhibition models and the best model was
determined by comparing each fit using Akaike’s method (AIC) (equations 24 and 25,
chapter 1).
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CHAPTER THREE: RESULTS AND DISCUSSION
Enzyme Purification
RhlI purification
Four hours of growth was required for the RhlI-containing strains in 1 L medium
to reach OD600 value between 0.6 and 0.8 for sufficient cell density. Physical lysis via
sonication and the subsequent centrifugation resulted in clear dull-yellow lysate. The
RhlI-containing plasmid also codes for maltose binding protein (MBP) for use with
amylose affinity column. The RhlI and MBP pair has a combined molecular weight of
65.5 kD, which was supported by the analysis of SDS-PAGE gel (Figure 22)

Figure 22.
SDS-PAGE gel of RhlI protein isolated using amylose
chromatography. Lane 1: EZ prestained protein ladder; Lane 2: RhlI column load runthrough; Lane 3: load wash; Lanes 4-8: Buffer A (50 mM Tris-HCl, pH 7.5, 0.2 M NaCl,
1 mM EDTA, 0.1 mM PMSF, 0.1 mM TLCK, 0.4 M sucrose, and 2.5% (v/v) glycerol)
+10 mM maltose elution fractions 1-5. RhlI + MBP has a combined molecular weight of
65.5 kD. The 100 kD ladder is the first one from the top, followed by 30 kD marker. The
thick bands in between the 100 and 30 kD marker, much closer to the 100 kD marker, are
presumed to be containing purified RhlI.
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Apo-ACP Purification
The cell culture reached optimal cell density indicated by OD600 = 0.6-0.8 within
4 hours of growth. Chemical lysis via B-PER, DNase, RNase, Lysozyme, and PMSF
followed by centrifugation was effective in producing clear dull-yellow lysate. Upon
addition of MgCl2 and MnSO4 to activate ACP-hydrolase, co-coded with apo-ACP gene
to convert holo-ACP to apo-ACP, the solution turned cloudy. A clear lysate was again
achieved after precipitating ACP-hydrolase using 2-propanol followed by centrifugation.
This solution was run through DE52 diaminoethyl cellulose anion exchange column for
purification. SDS-PAGE gel confirmed the isolation of apo-ACP at ~9 kD (Figure 23).

Figure 23.
SDS-PAGE gel of apo-ACP isolated with anion exchange
chromatography. Lane 1: EZ prestained protein ladder; Lane 2: Crude apo-ACP; Lane
3: load wash; Lanes 4-10: 10 mM lithium MES pH 6.1 + 0.5 M LiCl elution fractions 1,
3, 5, 7, 9, 11. The second-from-the-bottom ladder corresponds to 10 kD. The protein
bands aligned with the 10 kD marker are presumed to be apo-ACP (8.6 kD).
Alkyl-CoA Synthesis
In alkyl-CoA synthesis reaction, free-Coenzyme A (limiting reagent) is alkylated
with alkyl-bromides. As described in Chapters 1 and 2, DCPIP turns colorless upon
reaction with thiols. Therefore, upon adding a sample of the reaction mixture to an
aliquot of DCPIP, if no color change is observed, it would indicate that free-CoA, a thiol,
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was completely consumed and that the reaction went to completion. The alkyl-CoA
(inactive-CoA; ICoA) was isolated via HPLC using the Alkyl-CoA separation method
described in Chapter 2 and the fractions were collected using an automated fraction
collector. Since the compounds are run through a reverse-phase column, compounds with
longer alkyl-chain (more nonpolar) have longer retention time (RT) as compared to
ICoAs with shorter, less hydrophobic, alkyl-chains (Figure 24).

Figure 24.
Elution time of various alkyl-CoAs. The reverse-phase preparatory
column has higher affinity for more hydrophobic compounds, causing compounds with
longer alkyl chain, thus greater hydrophobicity, to have greater retention time.
Acyl/Alkyl-ACP Synthesis
Phosphopantetheinyl transferase, or Sfp, catalyzes the transfer of acyl-/alkylpantetheine from CoA nucleotide to ACP protein. Apo-ACP (limiting reagent) was
reacted with acyl-/alkyl-CoA in the presence of Sfp. Due to precipitation of highly
hydrophobic CoAs with acyl-/alkyl- chain of ten carbons or longer, C10-CoA and C12CoA were added to the reaction in portions over a 90-minute period to avoid having the
CoA crash out of the predominantly aqueous solvent. The synthesis of acyl-/alkyl-ACPs
were monitored by HPLC using the ACP separation method as described in Chapter 2.
Using the standard ACP separation method, apo-ACP elutes out at 7.8 minutes. The
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addition of pantetheine linker greatly reduces its overall hydrophobicity, causing holoand butanoyl-ACPs to have shorter RT than apo-ACP whereas acyl/alkyl-ACPs with
eight or longer carbon chain nonpolar enough to have longer RT than apo-ACP (Figure
25a). Whereas apo-ACP elutes out at 7.8 minutes, butanoyl-, octanoyl-, decanoyl-, and
dodecanoyl-ACPs elute out at 7.3, 8.0, 8.3, and 8.7 minutes, respectively. However,
hexyl- and hexanoyl-ACPs have nearly identical RT as apo-ACP, necessitating
separation using C6-ACP separation method with shallower solvent gradient (Figure
25b). In this method, apo-ACP elution time is 34 minutes, compared with 33 minutes for
hexanoyl-ACP. There is virtually no difference in the elution time between an acyl-ACP
and its alkyl-ACP counterpart (e.g. both butanoyl-ACP and butyl-ACP elutes out at 7.3
minutes). The reaction was deemed complete when the limiting reagent, apo-ACP, peak
at 7.8 min was completely depleted, which occurred in 3 hours or less. However, the
batch was deemed unusable if there was a significant peak present at 6.5 minutes,
corresponding to holo-ACP contamination. The solution became cloudy when
ammonium sulfate was added to precipitate Sfp. The precipitated transferase was then
removed with centrifugation. The clear lysate was run through 3 kD spin filtration
column to remove ammonium sulfate, CoA byproduct, and excess acyl-/alkyl-CoA. This
filtration process was repeated until the peak at 280 nm (corresponding to ACP) was at
least 10% greater than the peak at 260 nm (corresponding to CoA) as determined by the
UV-vis spectrophotometer.
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Figure 25.
Elution time of various acyl-/alkyl-ACPs. The more hydrophobic
compounds have higher affinity to the reverse-phase UHPLC column and have longer
retention time. The addition of the pantetheine linker greatly reduces the hydrophobicity
of ACP, (a) causing acyl-/alkyl-ACPs with four carbon chains or shorter to elute out
before apo-ACP and those with chains of eight carbons or longer to elute out after apoACP. (b) Hexanoyl-/hexyl-ACP has nearly identical retention time as apo-ACP thus
requiring the solvent gradient to shift over a longer time-period at a lower flowrate.
Small Molecule Synthesis
D-Homocysteine Thiolactone (Figure 19, Chapter 2)
Stereoisomerically pure D-homocysteine thiolactone was purified from a racemic
mixture of DL-homocysteine thiolactone by acylating the thiolactone headgroup with S(+)-2-methoxyphenylacetic acid in a EDC-coupled reaction to produce two diastereomers
with distinct differences in polarity that could be separated with column chromatography.
The EDC-coupled reaction produced white crystalline product easily soluble in
chloroform but not so much in the 7:3 hexane: ethyl acetate eluting solvent, thus the

57
diastereomer mixture was dissolved in minimal amount of chloroform and then loaded to
the silica gel column. The separation of the diastereomers via silica gel column was
confirmed with thin layer chromatography (TLC) with UV active silica with the 7:3
hexane: ethyl acetate eluent. Because there is only a small difference in the polarities of
the diastereomers, there were significant number of fractions with both products. The
fractions with the both diastereomers were collected and run through the silica gel
column again to fully isolate the desired product. In addition to comparing the polarity of
the diastereomers via elution time, the purity of the diastereomers was further confirmed
by comparing the melting point of each compound; (3S,2′S)-3-(2′-methoxy-2′-phenyl)acetamido-2-thiophenone (containing L-homocysteine thiolactone) had a melting point
of 160-164°C (literature value: 161-163°C57) whereas (3R,2′S)-3-(2′-methoxy-2′-phenyl)acetamido-2-thiophenone (containing D-homocysteine thiolactone) had a melting point
of 110-115°C (literature value: 109-111°C57). Once the D-homocysteine thiolactone
head-group was isolated and recrystallized in 2-propanol, its stereo purity was confirmed
by optical rotation measurement [𝛼]25
𝐷 -36.3 (0.05 mg/mL in H2O) (literature value: 21.757).
N-Acyl-D-Homocysteine Thiolactone (Figure 20, Chapter 2)
The DCC-coupled reaction resulted in colorless mixture with white cloudy urea
precipitate, which was easily removed via filtration with celite. Butyric acid was
sufficiently polar to yield clean N-Butanoyl-D-homocysteine thiolactone through a series
of aqueous washes with water, HCl (2M; 3x10 mL), NaHCO3 (saturated; 3x10 mL), and
brine (saturated; 3x10 mL). However, carboxylic acids with tails of six carbons or longer
were not polar enough to be removed by aqueous washes alone, requiring purification via
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silica gel column chromatography. The polarity between the N-acyl-D-homocysteine
thiolactones and their corresponding carboxylic acids were close enough that two runs
through the column were required to obtain a pure product.
N-(3-Oxoacyl)-D-Homocysteine Thiolactone (Figure 21, Chapter 2)
Meldrum’s acid acylation reaction resulted in a colorless mixture with white
cloudy urea precipitate, which was removed via celite filtration, which yielded a paleyellow flake-like product which was stored at -20 °C to protect the temperature sensitive
Meldrum’s acid. Refluxing the acylated Meldrum’s acid with the D-homocysteine
thiolactone head-group opened the Meldrum’s acid ring and attached the 3-oxoacyl tail to
the headgroup. The polarity of the N-(3-Oxoacyl)-D-homocysteine thiolactones and their
corresponding carboxylic acids were close enough that two runs through the silica gel
column were required to obtain a pure product.
Spectral Data
See Appendix for all Mass Spectrometry (Appendix A), NMR (Appendix B), and
UV-vis spectrophotometer (Appendix C) spectra.
AHL Analog Kinetics
Background rate
As reported previously, non-specific reduction of DCPIP is a major limitation of
the DCPIP colorimetric assay, which is compounded by significant levels of
contamination in commercially available SAM-Cl.53 To circumvent the issue, the
reaction mixture, except the enzyme, was incubated with DCPIP and the decrease in
absorbance at 600 nm was observed. The rate of decrease of absorbance flattens around
600 s (10 min) and the background rate in the 600-900 s range is equivalent of 0.013
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µM/min, about 5% of the lowest enzyme rate observed in this project (Figure 26).
Therefore, to minimize background rate interference, the reaction mixture was incubated
with DCPIP for 10 min before initiation with the enzyme.

Figure 26.
DCPIP background rate progress curve. The 100 µL reaction mixture
was composed of HEPES buffer (100 mM, pH 7.3), SAM (300 µM), butanoyl-ACP (30
µM), DCPIP (30 µM), and water. The absorbance at 600 nm was observed for 1200 s (20
min). The background rate flattens out at 600 s (10 min).
The Effects of AHL analogs on RhlI enzymatic rate
Previous studies have shown that RhlI activity is unaffected by butanoylhomoserine lactone (C4-HSL; compound 1), its native N-acyl-homoserine lactone (AHL)
product.36 To explore the components of the AHL structure that could be modified to
affect RhlI activity, the first set of AHL analogs were designed to test the effects of
alterations to the headgroup on RhlI enzymatic rate (Figure 27). The L-homoserine
lactone headgroup was modified in the lactone ring (compounds: 2-4, 8-12), the chirality
(compounds: 5, 12), and the tail-headgroup linkage (compounds: 6, 7, 10-12). While
most derivatives failed to effect RhlI, a change in the chirality and linkage (compounds 5
and 12) in AHL inhibited RhlI. Although analog 8, the thiolactone derivative, did not
inhibit RhlI, work from our collaborators have found thiolactone analogs to have
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significant antagonistic and agonistic effects on QS receptor proteins; therefore, we were
interested in exploring thiolactone analogs in an effort to discover compounds that could
inhibit both RhlI (AHL synthase) and RhlR (AHL receptor) simultaneously.43 The initial
study and previous findings prompted us to further expand the analog libraries with
alterations to the headgroup stereocenter, sulfonamide linkage between the headgroup
and the aliphatic chain, and thiolactone ring headgroup in the search for better RhlI
inhibitors. (for kinetics data, see Appendix, Figure C1)
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Figure 27.
Initial set of AHL-analogs and their effects. The initial rates of RhlI
with 300 µM of SAM and 14 µM of C4-ACP in the presence of 0-20 mM of the AHL
analogs were observed. Only the chiral and linkage changes (compounds 5 and 12)
caused inhibition. (Appendix Figure C1)
Acyl-L-homoserine lactone (L-HSL)
In many QS receptor studies, modifications to the acyl-chain had significant
antagonistic and agonistic effects on the receptor.43, 59 To determine whether the same is
true for RhlI, the native headgroup, L-HSL, was acylated with various acyl, 3-oxoacyl,
and 3-hydroxyacyl-chains (compounds 1,13-27; Figure 28). Regardless of the
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modification to the hydrocarbon chain, none of the sixteen analogs with the L-HSL
headgroup moiety inhibited RhlI. (Appendix Figure C2)
O

O

O
N
H

N
H

O

H

1
No effect
O
N
H

O

H

O
N
H

O

O

O

H

O

O

H

O

O
N
H

3

H

O

22
No effect

O

O
N
H

7

23
No effect

H

O

24
No effect

O

O
N
H

5

O

O
N
H

O
N
H

OH

O

H

21
No effect

O

5

O

H

17
No effect

O

O

H

20
No effect
O

N
H

7

19
No effect

O
N
H

O

O
N
H

11

18
No effect
O

O

H

O

O

H

O

H

O

16
No effect

O

N
H

2

O
N
H

5

O

14
No effect

O

15
No effect

9

O

H

13
No effect

O

3

O

O

H

O

25
No effect

OH

O
N
H

7

26
No effect

OH

O

H

O

O

O
N
H

9

H

O

27
No effect

Figure 28.
Effects of acyl-L-homoserine lactones, 3-oxoacyl- and 3-hydroxyacylL-homoserine lactones on RhlI initial rate. The initial rates of RhlI in the presence of
0-2 mM of acyl-L-homoserine lactones of various acyl-chain lengths were observed.
Acyl-L-homoserine lactones with chains between 4 and 16 carbons long did not inhibit
RhlI. (Appendix Figure C2)
Acyl-D-homoserine lactone (D-HSL)
While none of the eight acyl-L-HSLs (compounds: 1, 13-19) inhibited RhlI, two
analogs out of seven acyl-D-HSLs were found to inhibit the enzyme: compounds 5, IC50:
687.7 ± 90.7 µM, and compound 31, IC50: 20.2 ± 10.1 µM (Figure 29). Interestingly,
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while compound 5 has a butanoyl tail, which is the native acyl-chain for the Rhl QS
system, compound 31 has a phenylbutanoyl chain, which should be too large to bind to
RhlI acyl-chain binding pocket. (Appendix Figure C3)
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Figure 29.
Effects of acyl-D-homoserine lactones. The initial rates of RhlI in the
presence of 0-2 mM of acyl-D-homoserine lactones of various acyl-chain lengths were
observed. Of these compounds, acyl-D-homoserine lactones with butanoyl and butylphenyl chain (compounds 5 and 31) inhibited RhlI, with the longer/bulkier compound 31
having lower IC50 value (20.2 ± 10.1 µM vs. 687.7 ± 90.7 µM). (Appendix Figure C3)
3-oxoacyl-D-HSL
However, the more interesting pattern emerges with 3-oxoacyl-D-HSL derivatives
(Figure 30). While compound 35, medium chain-length analog (3-oxoC8-D-HSL),
inhibited RhlI (IC50: 282.0 ± 34.1 µM), a shorter chain derivative, compound 34 (3oxoC6-D-HSL), activated RhlI (EC50: 224.4 ± 55 µM). This discovery of an activator,
suggests that the small molecule modulators are perhaps binding to an allosteric or
nonspecific binding site. The presence of a nonspecific binding site could explain how
compound 31, with its large tail, binds with and inhibits RhlI. (Appendix Figure C4)
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Figure 30.
Effects of 3-oxoacyl-D-homoserine lactones. The initial rates of RhlI in
the presence of 0-2 mM of 3-oxoacyl-D-homoserine lactones of various acyl-chain
lengths were observed. Of these compounds, acyl-D-homoserine lactones with hexanoyl
chain (compound 34) activated RhlI initial rate (EC50: 224.4 ± 55 µM) whereas the one
with octanoyl chain (compound 35) inhibited RhlI (IC50: 282.0 ± 34.1 µM) and the one
with dodecanoyl chain did not affect RhlI enzyme rate. (Appendix Figure C4)
Acyl-sulfonamide-DL-HSL
Unlike the pattern found with acyl-HSLs, RhlI inhibitors were found from both L
and D sulfonamide derivatives (Figure 31). Compound 12, a sulfonamide-D-HSL analog,
was found to be a more potent inhibitor than compound 37, a sulfonamide-L-HSL analog,
with IC50 values of 170.9 ± 98.0 µM vs. 345.3 ± 79.3 µM, respectively. However, no
other variations in the aliphatic chain with sulfonamide linkage was found to inhibit RhlI.
(Appendix Figure C5)
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Figure 31.
Effects of L and D sulfonamides. The initial rates of RhlI in the presence
of 0-2 mM of L and D sulfonamide-homoserine lactones of various chain lengths were
observed. The compounds with the short chains, butylsulfonamide-L-homoserine lactone
(compound 37) and propylsulfonamide-D-homoserine lactone (compound 12), inhibited
RhlI with IC50 values of 345.3 ± 79.3 µM and 170.9 ± 98.0 µM, respectively. (Appendix
Figure C5)
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Acyl- and 3-oxoacyl-L-homocysteine thiolactone
Although compound 8 did not inhibit RhlI, expansion of the hydrocarbon tail
library yielded two inhibitors: compounds 46 and 55 with IC50 values of 387.3 ± 88.6 µM
and 621.2 ± 49.5 µM, respectively (Figure 32). Again, contrary to initial expectations, it
is the long-chain analogs that inhibit RhlI while the short-chain derivatives fail to effect
RhlI activity. Furthermore, this is the first category of compounds with a L-stereocenter
headgroup in which multiple inhibitors were discovered. (Appendix Figure C6)
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Figure 32.
Effects of acyl- and 3-oxoacyl-L-homocysteine thiolactones. The initial
rates of RhlI in the presence of 0-2 mM of acyl- and 3-oxoacyl-L-homocysteine
thiolactones of various acyl-chain lengths were observed. Of these compounds, only C12L-homocysteine thiolactone and 3-oxo-C12-L-homocysteine thiolactone (compounds 46
and 55), the ones with the longest straight chain, inhibited RhlI. Of these two compounds,
one with the acyl-chain had lower IC50 value than the one with the 3-oxoacyl-chain (IC50:
387.3 ± 88.6 µM vs. 621.2 ± 49.5 µM). (Appendix Figure C6)
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Acyl- and 3-oxoacyl-D-thiolactone
Following the pattern found with L- and D-HSL derivatives, D-thiolactone
analogs produced much more potent inhibitors than L-thiolactones (Figure 33).
Compared with IC50 value of 387.3 ± 88.6 µM for compound 46 (C12-L-thiolactone),
compound 60 (C12 D-thiolactone) had IC50 value of 11.4 ± 1.5 µM, a 34-fold decrease.
And whereas compound 55 (3-oxoC12-L-thiolactone) had IC50 value of 621.2 ± 49.5 µM,
compound 64 (3-oxoC12-D-thiolactone) was found to have a much lower IC50 value
127.4 ± 70.2 µM, close to 5-fold decrease. However, the most interesting phenomena
occurred with short and medium-chain derivatives. As seen with 3-oxoacyl-D-HSLs,
which were found to be activating with a shorter chain and inhibiting with a longer chain,
3-oxoC6, 3-oxoC8, and 3-oxoC10-D-thiolactones (compounds 61-63) activated while 3oxo C12-D-thiolactone (compound 64) inhibited RhlI. Interestingly, as the chain
lengthened from 3-oxoC6 to 3-oxoC8 and 3-oxoC10, the activation potency increased
indicated by EC50 values decreasing 1506 ± 109.9 µM, 854.5 ± 74.4 µM, and 57.1 ± 22.7
µM. (Appendix Figure C7)
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Figure 33.
Effects of acyl- and 3-oxoacyl-D-homocysteine thiolactones. The initial
rates of RhlI in the presence of 0-2 mM of acyl- and 3-oxoacyl-D-homocysteine
thiolactones of various acyl-chain lengths were observed. Of these compounds,
dodecanoyl-D-homocysteine thiolactone and 3-oxo-dodecanoyl-L-homocysteine
thiolactone (compounds 60 and 64), the ones with the longest straight chain, inhibited
RhlI. As with their L-counterpart, one with the acyl-chain had lower IC50 value than the
one with the 3-oxoacyl-chain (IC50: 11.4 ± 1.5 µM vs. 127.4 ± 70.2 µM). The shorterchain 3-oxoacyl-D-homocysteine thiolactones (compounds 61-63) activated RhlI activity,
with the EC50 values decreasing as the carbon chain lengthened. (Appendix Figure C7)
Acyl-Cyclopentanamide
Since thiolactone derivatives inhibited and activated RhlI to a greater degree than
lactone analogs, the effects of cyclopentyl headgroup was tested to explore further
increase in headgroup hydrophobicity (compounds 4, 65-68; Figure 34). However, no
cyclopentyl derivatives effected RhlI activity. (Appendix Figure C8)
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Figure 34.
Effects of acyl-cyclopentanamide on RhlI activity. The initial rates of
RhlI-catalyzed C4-HSL synthesis were similar with and without acyl-cyclopentanamides,
suggesting no inhibitory effect of this class of molecules on RhlI activity. (Appendix
Figure C8)
Non-lactone derivatives
While cyclopentyl derivatives tested the effects of nonpolar headgroups, various
non-lactone analogs were designed to test headgroups of various configurations and
hydrophilicity (compounds 2, 3, 9-11, 69-73; Figure 35). None of these non-lactone
compounds inhibited RhlI. (Appendix Figure C9)
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Figure 35.
Effects of non-lactone AHL analogs on RhlI activity. The initial rates of
RhlI in the presence of 0-2 mM of various non-lactone AHL analogs were observed and
none of them inhibited RhlI. (Appendix Figure C9)
Headgroup vs Tail chain effects
Thus far, only lactone and thiolactone derivatives modulated RhlI rate (activation
and inhibition), and the variation in the acyl-chain enhanced the effect. To check if the
inhibitory effects observed for lactone and thiolactone derivatives described above was
caused by nonspecific binding of headgroup or fatty acid to the synthase enzyme, the
initial rate of RhlI was observed in the presence of the headgroup (L-HSL, D-HSL, Lthiolactone, and D-thiolactone; compounds 74-77), the fatty acid chain tail (butyric,
hexanoic, octanoic, decanoic, and dodecanoic acid; compounds 78-82), or both (Dthiolactone + dodecanoic acid, compounds 77 + 82, corresponding to compound 60;
Figure 36). None of these kinetic assays resulted in the inhibition of RhlI, suggesting that
both the headgroup and the aliphatic tail moieties must be covalently linked to each other
to observe the inhibition/activation effects described above. (Appendix Figure C10)
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Figure 36.
Effects of headgroup and tail moieties in isolation on RhlI initial rate.
the initial rates of RhlI in the presence of 0-2 mM of L and D homoserine lactone and
homocysteine thiolactone headgroups and various carboxylic acid tail groups were
observed. Furthermore, the initial rates of RhlI were observed in the presence of 0-2 mM
of both compounds 77 and 82, which was analogous to compound 60 which did inhibit
RhlI. None of these compounds inhibited RhlI, indicating that neither the acyl-chain nor
the headgroup alone has sufficient binding affinity to RhlI to cause inhibition. (Appendix
Figure C10)
Determining the mode of inhibition
As described in chapter 1, RhlI is an ordered bi-ter enzyme with C4-ACP binding
second and C4-L-HSL released second (Figure 37). AHL analogs are expected to
compete for C4-L-HSL binding site. As such, C4-ACP and AHL analogs bind to
different RhlI forms (C4-ACP to EA form and analogs to ER form), which would cause
intercept-effect in a double reciprocal plot (Chapter 1, p. 21). Furthermore, C4-ACP
binding and C4-L-HSL release are separated by a product release step in both the forward
and reverse directions; therefore, C4-ACP binding and AHL analog binding are
irreversibly connected, which would be manifested by a lack of slope-effect in a double
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reciprocal plot (Chapter 1, p. 20). Intercept-effect without slope-effect would produce a
set of parallel lines, indicative of uncompetitive inhibition.

Figure 37.
Cleland diagram of RhlI catalyzed reaction. “E” denotes RhlI while
“A,” “B,” “P,” “Q,” and “R” represents SAM, C4-ACP, holo-ACP, C4-L-HSL, and
MTA, respectively.
The Lineweaver-Burk plot of initial RhlI rate versus variable C4-ACP
concentrations at various fixed C12-D-thiolactone (Figure 38a) or 3-oxoC12-Dthiolactone (Figure 38b) concentrations show a set of parallel lines, indicative of
uncompetitive-mode of inhibition which supports the initial expectation that AHL
analogs are binding to C4-L-HSL binding site (ER enzyme conformation in Figure 31
above). Further analysis using the Akaike’s method (AIC; see equations 24, 25), confirms
that all the inhibition data is best fitted by uncompetitive inhibition model (Table 10).
Moreover, as predicted by the trend in IC50 values, C12-D-thiolactone (Ki: 86.2 ± 9.6
µM) has higher binding affinity than 3-oxoC12-D-thiolactone (Ki: 431.6 ± 30.8 µM)
(Table 11).
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Figure 38.
Double Reciprocal Plot of RhlI activity with varying C4-ACP
concentrations and various fixed AHL analog concentrations. Double reciprocal of
the initial rate of RhlI against C4-ACP concentration in the presence of various fixed
concentrations of (a) compound 60 (C12-D-thiolactone) and (b) compound 64 (3oxoC12-D-thiolactone) was plotted. The fixed AHL analog concentrations were chosen
to be 0, below the IC50 value, around the IC50 value, and two above the IC50 value. While
keeping the AHL analog concentration fixed, C4-ACP concentration was varied from 2
to 20 µM. The inverse of the initial rate was plotted against inverse of the C4-ACP
concentration which revealed a set of parallel lines, indicative of uncompetitive mode of
inhibition.
Table 10.

Determining best fit model for the mode of inhibition using AIC

Analog
Best fit
Ua vs Cb
60
Uncompetitive
>99.99% U
64
Uncompetitive
>99.99% U
a = Uncompetitive mode of inhibition
b = Competitive mode of inhibition
c = Mixed mode of inhibition
d = Noncompetitive mode of inhibition

U vs Mc
78.81% U
54.69% U

U vs Nd
95.84% U
68.30% U

Table 11.
Effect of AHL analogs on RhlI initial enzyme rate with variable C4ACP concentration.
Analog
60
64

IC50 (µM)
11.4 ± 1.5
127.4 ± 70.2

Ki (µM)
86.2 ± 9.6
431.6 ± 30.8

Mode of Inhibition
Uncompetitive
Uncompetitive

AHL analog Trends
Chain length effect
RhlI inhibition was primarily observed with D-HSL, L-thiolactone, and Dthiolactone headgroups. With each headgroup, a short-chain derivative resulted in no or

72
weak inhibition while a long or bulky-chain analog displayed much more potent
inhibitory effects (Table 12). Moreover, if the short-chain analog does inhibit, it achieves
greater maximum inhibition (maximum % inhibition). This pattern of long-chain
derivatives having lower IC50 is highly surprising. The acyl-chain moiety is expected to
bind in the small acyl-chain binding pocket of RhlI, specific for a butanoyl chain of the
C4-ACP native substrate, used by its native substrate/product. In the absence of the
crystal structure of RhlI, this phenomenon can be explained by several hypotheses: (1)
both the kon and koff values could be higher for longer chains or (2) the longer acyl-chains
are binding to a nonspecific or an alternate acyl-chain binding site with higher affinity
than the acyl-chain binding pocket. This acyl-chain length pattern of longer chains better
inhibiting RhlI can be further studied by analyzing RhlI enzymatic rate with nonnative
acyl-ACP substrates and the inhibition patterns of inhibitors of various hydrocarbon tail
length. Acyl carrier protein (ACP) engulfs the acyl-chain until the proteins binds to the
appropriate enzyme active site and then releases the acyl-chain. Therefore, any acyl-chain
binding site must be specific and close to ACP binding site. Long-chain acyl-ACP
substrates undergo RhlI catalysis with decreasing Km as the acyl-chain length is increased
(see “Determining Kinetic Constants with various Acyl-ACPs” section below). Similar
pattern (decrease in Ki and IC50 with increase in acyl-chain length) was observed with
longer chain alkyl-ACPs and alkyl-CoAs, thus ruling out inhibition due to nonspecific
binding for long-chain analogs. Therefore, the acyl-chain must bind at or somewhere
close to the acyl-chain binding pocket in RhlI.
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Table 12.

Trends with variations in the acyl-chain length/size.
IC50 (µM)
% Inhibition

Compound
O

O
N
H

687.7 ± 90.7
40%

O

H

IC50 Trendsa
Weaker

5
O

O
N
H

O

H

20.2 ± 10.1
25%

31
O

S
N
H

None
0%

O

H

Stronger
No Inhibition

43
O

S
N
H

7

387.3 ± 88.6
60%

O

H

46
O

O

No Inhibition

S
N
H

None
0%

O

H

Weak Inhibition

53
O

O

S
N
H

5

O

H

55
O

621.2 ± 49.5
60%

S
N
H

None
0%

O

H

Weak Inhibition
No Inhibition

56
O

7

S
N
H

H

O

11.4 ± 1.5
40%

60
a = On a relative scale

Weak Inhibition

Acyl-chain vs 3-oxoacyl-chain effects
A very interesting pattern develops with 3-oxoacyl-chain derivatives (Table 13).
Compared with their acyl-chain counterparts, 3-oxoacyl analogs have much less
inhibitory characteristics, indicated by their significantly higher IC50 values (621.2 ± 49.5
µM vs 387.3 ± 88.6 µM for compounds 55 and 46, respectively; and 127.4 ± 70.2 µM vs
11.4 ± 1.5 µM for compounds 64 and 60, respectively). Furthermore, varying the chain
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length significantly alters its behavior. As discussed above, shortening the chain seems to
decrease the inhibitory characteristics of the analog. The decrease in the inhibitory
characteristic due to having a carbonyl at the C3 position combined with the short-chain
effect appears to have a synergistic result of activating RhlI activity. While 3-oxoC8-DHSL (compound 35) inhibited RhlI with IC50 value of 282.0 ± 34.1 µM, shortening the 3oxoacyl-chain to 3-oxoC6 chain (compound 34) caused the derivative to activate RhlI
with EC50 value of 224.4 ± 55 µM. The same pattern holds true with 3-oxoacyl-Dthiolactone analogs. While 3-oxoC12-D-thiolactone, the long-chain derivative, inhibited
RhlI with IC50 value of 127.4 ± 70.2 µM, shorter chain analogs activated RhlI. However,
until the long-chain effect caused 3-oxoC12-D-thiolactone (compound 64) to be an
inhibitor, lengthening the chain from 3-oxoC6-D-thiolactone (compound 61) to 3-oxoC8D-thiolactone (compound 62) and then to 3-oxoC10-D-thiolactone (compound 63)
heightened RhlI activation, shown by decreasing EC50 values of 1506 ± 109.9 µM, 854.5
± 74.4 µM, and 57.1 ± 22.7 µM, respectively. Although the EC50 values decrease as the
chain length increase, the maximum activation also decrease as the chain lengthens.
Activation is usually indicative of a presence of an allosteric site. Moreover, if the 3oxoacyl-chains bind to and occupy the RhlI acyl-chain binding pocket, it is inconceivable
that the acyl-chain from C4-ACP can also bind to the acyl-chain binding pocket, further
supporting hypothesis 2.
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Table 13.

Patterns in varying effects of acyl- and 3-oxoacyl-chain derivatives.
IC50/EC50 (µM)
% Inhibition/Activation

Compound
O

O

O
N
H

EC50: 224.4 ± 55
100% A

O

H

IC50 and EC50
Trendsa
Activation

34
O

O

O
N
H

O

H

35
O

O

S
N
H

5

IC50: 282.0 ± 34.1
60% I

O

H

IC50: 621.2 ± 49.5
60% I

Inhibition
Weaker
Inhibition

55
O

S
N
H

7

IC50: 387.3 ± 88.6
60% I

O

H

46
O

O

S
N
H

5

O

H

IC50: 127.4 ± 70.2
50% I

Stronger
Inhibition
Weaker
Inhibition

64
O

S
N
H

7

IC50: 11.4 ± 1.5
30% I

O

H

60
O

O

S
N
H

EC50: 1506 ± 109.9
100% A

O

H

Stronger
Inhibition
Weak Activation

61
O

O

S
N
H

H

EC50: 854.5 ± 74.4
60% A

O

62
O

O

S
N
H

3

H

O

EC50: 57.1 ± 22.7
40% A

Strong Activation

63
O

5

O

S
N
H

64
a = On a relative scale

H

O

IC50: 127.4 ± 70.2
50% I

Inhibition
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Headgroup chirality effect
The D-stereocenter derivatives were found to have much greater effect on RhlI
enzymatic rate than their L-stereocenter counterparts (Table 14). While the native AHL
product, C4-L-HSL, did not inhibit RhlI, change of the headgroup chirality to C4-D-HSL
transformed it to a weak inhibitor. Whereas both C12-L-thiolactone (compound 60) and
3-oxoC12-L-thiolactone (compound 64) both inhibited RhlI, the IC50 value dropped by
34-fold and 5-fold, respectively for their corresponding D-stereocenter counter parts
(compounds 46 vs 60 and 55 vs 64).

Table 14.

Effects of varying the headgroup chirality from L to D stereoisomer.
IC50 (µM)
% Inhibition

Compound
O

No Inhibition

O
N
H

None
0%

O

H

IC50 Trendsa

1
O

O
N
H

687.7 ± 90.7
40%

O

H

5
O

S
N
H

7

387.3 ± 88.6
60%

O

H

Weak Inhibition
Weaker
Inhibition

46
O

S
N
H

7

11.4 ± 1.5
30%

O

H

60
O

O

S
N
H

5

H

O

621.2 ± 49.5
60%

Stronger
Inhibition
Weaker
Inhibition

55
O

5

O

S
N
H

64
a = On a relative scale

H

O

127.4 ± 70.2
50%

Stronger
Inhibition
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Headgroup hydrophilicity effect
Reducing the hydrophilicity of the headgroup by replacing homoserine lactone
with homocysteine thiolactone head made a marked increase in the magnitude of the
effect on RhlI inhibition and activation (Table 15). While no L-HSL derivatives inhibited
RhlI, C12-L-thiolactone and 3-oxo-C12-L-thiolactone were shown to be inhibitors of the
AHL synthase. With D-HSL derivatives, IC50 values ranged from 687.7 to 20.2 µM
(compounds 5 and 31), which was significantly reduced to 127.4 to 11.4 µM (compounds
64 and 60) by replacing D-HSL with a more hydrophobic D-thiolactone headgroup.
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Table 15.

The effect of headgroup hydrophobicity on RhlI inhibition.
IC50 (µM)
% Inhibition

Compound

IC50 Trendsa
No Inhibition

No effect
0%
All 3-oxoacyl-/3-hydroxyacyl/acyl-L-HSL
O

O

S
N
H

5

O

H

621.2 ± 49.5
60%

Weaker
Inhibition

55
O

S
N
H

7

387.3 ± 88.6
60%

O

H

46
O

O
N
H

687.7 ± 90.7
40%

O

H

Stronger
Inhibition
Weaker
Inhibition

5
O

O

O
N
H

O

H

282.0 ± 34.1
60%

35
O

O
N
H

O

H

20.2 ± 10.1
25%

31
O

O

S
N
H

5

O

H

127.4 ± 70.2
60%

64
O

7

60
a = On a relative scale

S
N
H

H

O

11.4 ± 1.5
60%

Stronger
Inhibition

Determining Kinetic Constants with various Acyl-ACPs
To determine the effect of the acyl-chain variation on acyl-ACP substrate
catalytic efficiencies, RhlI activity was assayed with butanoyl-ACP (compound 83;
Chapter 1, Table 6), the native substrate, and then with four long-chain substrates: C6ACP, C8-ACP, C10-ACP, and C12-ACP (compounds 84-87). The reaction setup was
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based on published reaction conditions for previous studies on RhlI with its native C4ACP substrate. The acyl-ACP was the variable substrate while SAM was kept to 300 µM
(Figure 39). As expected, the highest initial enzyme rate was achieved with the native
substrate, C4-ACP, with a kcat value of 3 ± 0.3 min-1. This was followed by kcat values of
0.86 ± 0.03 min-1, 0.64 ± 0.02 min-1, 0.39 ± 0.01 min-1, and 0.61 ± 0.01 min-1 for C6-, C8, C10-, and C12-ACPs, respectively. The Km value for the native product was found to be
7 ± 2 µM. Typically, non-native substrates have higher Km value than that of the native
substrate.22 However, contrary to expectation, the Km value decreased as the acyl-chain
lengthened: 1.2 ± 0.2 µM for C6-ACP, 0.21 ± 0.06 µM for C8-ACP, 0.16 ± 0.03 µM for
C10-ACP, and 0.26 ± 0.05 µM for C12-ACP. Although both Km and kcat values both
decreased, Km dropped more precipitously, causing the catalytic efficiency, determined
by kcat/Km, to be much greater for the non-native substrate than that of the native
substrate as summarized in Table 16 (Figure 40).
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Figure 39.
Substrate-velocity curves of RhlI with native and nonspecific acylACP substrates. RhlI initial rates as a function of acyl-ACP substrate concentration at
fixed 300 µM SAM. (a) varying [C4-ACP] and 0.3 µM RhlI, (b) varying [C6-ACP] and
0.9 µM RhlI, (c) varying [C8-ACP] and 0.9 µM RhlI, (d) varying [C10-ACP] and 0.9 µM
RhlI, and (e) varying [C12-ACP] and 0.9 µM RhlI. As the acyl-chain length of acyl-ACP
increases, Vmax is reached at lower acyl substrate concentrations, indicative of decreasing
Km values.
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Figure 40.
Trends in kcat, Km, and kcat/Km values of RhlI with various acyl
substrates. As the acyl-chain deviates further from the native substrate, both the (a) kcat
and the (b) Km values decrease. However, Km drops much faster than kcat, which leads to
(c) the catalytic efficiency, kcat/Km to, rise with longer acyl moiety.
Table 16.

RhlI initial enzyme rate with various acyl-ACP substrates

[RhlI]
(µM)
C4-ACP
0.3
C6-ACP
0.9
C8-ACP
0.9
C10-ACP
0.9
C12-ACP
0.9
a = [(kcat/Km)/0.36]
Acyl-ACP

kcat
(min-1)
2.6 ± 0.3
0.86 ± 0.02
0.66 ± 0.02
0.378 ± 0.009
0.60 ± 0.01

Km
(µM)
7±2
1.2 ± 0.2
0.40 ± 0.06
0.14 ± 0.04
0.26 ± 0.03

kcat/Km
(µM-1 min-1)
0.36 ± 0.01
0.719 ± 0.003
1.655 ± 0.006
2.71 ± 0.02
2.324 ± 0.006

kcat/Km
(Relative)a
100.0
197.4
454.1
743.2
637.6

Crystal structures have shown many AHL synthases to have similar structure, all
having specific ACP binding site, SAM binding site, and acyl-chain binding pocket.60-63
The acyl-chain binding pocket is easily recognizable by its V-cleft shape, which has a
definite spatial limitation to only accommodate acyl-chains of specific size. Moreover,
previous studies from the Nagarajan laboratory have shown that variations in the acylchain from the native substrate significantly reduce the enzymatic rate of AHL
synthases.22, 60 This pattern of behavior allows the bacteria to discriminate against the
synthesis of wrong signals, conserve resources, and increase the signal-to-noise ratio of
its own signal molecules. Therefore, the higher catalytic efficiency non-native acyl
substrate with RhlI poses a serious conundrum. One possible cause for this phenomenon
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could be with the ACP protein. Pseudomonas aeruginosa genome codes for three
different acyl carrier proteins: ACP1, ACPP, and ACP3.51 RhlI has been shown to react
with C4-ACP1 and C4-ACPP substrates with comparable catalytic efficiency but with
much greater catalytic efficiency than E. coli ACP-using substrate, which, in turn, has
much higher catalytic efficiency than C4-ACP3. However, this work was conducted
using E. coli ACP since P. aeruginosa ACPs and E. coli ACP share similar sequences
and to provide a common reference point to compare various AHL synthases (Figure 41).
Mair Churchill’s work with LasI (another AHL synthase found in P. aeruginosa) showed
that when LasI is expressed in E. coli with access to E. coli ACP only, the amount of
non-native AHL products is significantly higher than when LasI is expressed in P.
aeruginosa (Figure 42).64 Additionally, alkyl-CoA inhibition test (see Alkyl-CoA
inhibition section below) also seems to indicate that the ACP moiety plays an important
role in binding with RhlI. Therefore, the pattern of higher catalytic efficiency with
longer-chain acyl-ACP could be an artifact of using a non-native ACP and could be
removed by using P. aeruginosa ACP. Nevertheless, regardless of the ACP-effect, that
RhlI can accommodate long acyl-chain is surprising. As noted above, this phenomenon
can be explained if longer acyl-chains have higher koff rate (hypothesis 1) or if RhlI has
an allosteric site with equal or higher affinity for acyl-chains of various length than the
acyl-chain binding pocket (hypothesis 2). Under hypothesis 1, the increasing catalytic
efficiencies with longer acyl-chains could be due to higher kon rate while the decreasing
kcat rate could be caused by higher koff value. If hypothesis 2 is correct, it is possible that
the allosteric site promotes binding while the acyl-chain binding pocket promotes
reaction catalysis, analogous to kinetic vs. thermodynamic controls of reaction. The
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feasibility of these proposals was examined by analyzing the inhibition patterns of
inhibitors of various hydrocarbon tail length.

Figure 41.
Alignment of amino acid sequence of P. aeruginosa ACP1, ACPP,
ACP3, and E. coli ACP. The conserved residues are noted with an asterisk (*), mostly
conserved residues with a colon (:), and semi-conserved residues with a period (.).

Figure 42.64 Various AHL products of LasI. AHL profiles of (a) E. coli strain and (b)
P. aeruginosa strain were determined by liquid chromatography-mass spectrometry (LCMS). With access to native P. aeruginosa ACP, 3-oxoC12 HSL is the major AHL
product with limited amount of other AHLs. However, with E. coli ACP, there are
significant amounts of non-native AHL formation, signifying that ACP plays a significant
role in acyl-ACP specificity found in AHL synthases.
Alkyl-ACP Inhibition
The effect of hydrocarbon chain length was tested using alkyl-ACPs, also known
as inert-ACP or IACP. The removal of the carbonyl group from acyl-ACP converts the
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highly reactive thioester bond to relatively nonreactive thioether bond, making alkylACPs inactive analogs of acyl-ACP (Figure 43). The IC50 values of butyl-, hexyl-, octyl-,
and decyl-ACPs (compounds 88-91; Chapter 1, Table 6) with RhlI were determined to be
9.9 ± 4 µM, 0.74 ± 0.4 µM, 0.068 ± 0.02 µM, and 0.102 ± 0.04 µM, respectively (Table
17; Figure 44). Although the IC50 values decrease as the alkyl chain lengthens, the
maximum inhibition (indicated by %Rate) also decrease from 50% inhibition with C4IACP to 20% inhibition with all other IACPs (Table 17). This pattern of partial inhibition
suggests the presence of less active form of enzyme, indicative of allosteric inhibition.

Figure 43.
Designing inactive acyl-ACP analog. (a) In acyl-ACP, the carbonyl
group is a part of unstable thioester bond and creates a zone of electronegativity suitable
for nucleophilic attack. However, (b) the removal of the carbonyl group in alkyl-ACP
forms relatively stable thioether bond unfavorable to nucleophilic attack, thus forming
inert-ACP (IACP) analog of the acyl substrate.
Table 17.

Effect of IACP on RhlI initial enzyme rate.

IACP
C4-IACP
C6-IACP
C8-IACP
C10-IACP

IC50 (µM)
9.9 ± 4
0.74 ± 0.4
0.058 ± 0.02
0.102 ± 0.04

% Inhibition
50
20
20
20

Ki (µM)
15.9 ± 0.9
10.6 ± 1.1
6.5 ± 0.7
4.8 ± 0.3
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Figure 44.
IC50 test of various IACPs. The initial rate of RhlI with 300 µM of SAM
and 14 µM of C4-ACP in the presence of varying concentrations of (a) C4-, (b) C6-, (c)
C8-, and (d) C10-IACPs were determined. Whereas C4-IACP, the native substrate
analog, achieved the maximum inhibition (~50% inhibition compared to ~20% for all
others), other IACPs reached minimum activity at much lower inhibitor concentration.
Given that these four IACPs all inhibit RhlI, the mode of inhibition of these
IACPs could shed light to how RhlI copes with longer acyl-chains. Competitive
inhibition would definitively indicate that the IACPs are competing with butanoyl-ACP
for the same binding site and that RhlI acyl-chain binding pocket can accommodate
longer chains. On the contrary, uncompetitive mode of inhibition could be a result of the
IACP binding after AHL departs from the active site (hypothesis 1) or it could signify
that the IACP is not competing for the acyl-chain binding pocket and support the
hypothesis of longer chains binding to nonspecific site. Similarly, noncompetitive
inhibition could be a result of the inhibitor-free enzyme (EI) complex formed before
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E∙SAM complex formation (hypothesis 1) or if the inhibitor binding to the hypothetical
alternate/allosteric acyl-chain binding site (hypothesis 2). Plotting the double reciprocal
(Lineweaver-Burk plot) of initial RhlI rate versus variable C4-ACP concentrations at
various fixed IACP concentrations show a set of lines intersecting each other at the xaxis, indicative of noncompetitive-mode of inhibition (Figure 45). Further analysis using
the Akaike’s method (AIC; see equations 24, 25), confirms that all the inhibition data is
best fitted by noncompetitive inhibition model (Table 16). This finding is especially
surprising for C4 IACP, since its similarity with the native substrate, C4-ACP, led to the
prediction that would competitively inhibit RhlI activity. As predicted by the IC50 values,
Ki values decrease as the alkyl-chain lengthened (Table 18). If the inhibition is due to
alkyl-ACP binding to free RhlI before SAM binding with RhlI, the drop in the overall
inhibition with longer alkyl chains could be due to higher koff rate while the decrease in
Ki (Ki = koff/kon) could be a result of long-chain ACPs having even higher kon rate.
However, the noncompetitive mode of inhibition and the drop in both Ki and overall
inhibition could be due to hydrocarbon chains binding with equal or higher affinity to an
alternative acyl-chain binding sites than to the acyl-chain binding pocket. Although the
alternative pocket is yet to be identified, inhibition data with IACPs and ICoAs (see
“Alkyl-CoA Inhibition” section below) suggest that the acyl-chain binding pocket of the
alternative binding site would most likely be close enough or overlap with the native
acyl-chain pocket in RhlI.
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Figure 45.
Double Reciprocal Plot of RhlI activity with varying C4 -CP
concentrations and various fixed IACP concentrations. Double reciprocal of initial
rate of RhlI activity vs. C4-ACP concentration in the presence of various fixed
concentrations of (a) C4-IACP, (b) C6-IACP, (c) C8-IACP, and (d) C10-IACP was
plotted. The fixed IACP concentrations were chosen to be 0, below the IC50 value, around
the IC50 value, and two above the IC50 value. While keeping the IACP concentration
fixed, C4-ACP concentration was varied from 2 to 20 µM. The inverse of the initial rate
was plotted against inverse of the C4-ACP concentration which revealed a set of lines
intersecting near the x-axis, indicative of noncompetitive mode of inhibition.
Table 18.

Determining best fit model for the mode of inhibition using AIC

Analog
Mode
Na vs Cb
C4-IACP
Noncompetitive
>99.99 N
C6-IACP
Noncompetitive
99.87 N
C8-IACP
Noncompetitive
99.87 N
C10-IACP
Noncompetitive
>99.99 N
a = Noncompetitive mode of inhibition
b = Competitive mode of inhibition
c = Uncompetitive mode of inhibition
d = Mixed mode of inhibition

N vs Uc
99.99 N
91.03 N
82.48 N
96.94 N

N vs Md
67.00 N
74.41 N
75.70 N
75.72 N

A pure noncompetitive mode of inhibition could be a result of nonspecific, nonmechanistic enzyme deactivation. To determine whether IACP inhibition is a specific
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effect, RhlI was incubated with C4-IACP and C8-IACP for 0 to 60 min and the IC50 was
taken at various time points. Preincubation of RhlI with IACP did not significantly alter
the inhibitory effects of IACPs, indicating that the inhibition was due to specific binding
of IACP to RhlI (Figure 46).
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Figure 46.
Time-dependency of IACP inhibition. RhlI was preincubated with
varying concentrations of (a) C4- and (b) C8-IACPs for 0 to 60 minutes. The AHL
synthase reaction was initiated by the addition of RhlI + IACP mixture to reaction
mixtures consisting of 300 µM SAM and 14 µM C4-ACP. With both C4- and C8-IACP,
the variations in RhlI activity remained under 5% as incubation time changed from 0 to
60 minutes, eliminating the possibility of nonspecific, nonmechanistic inhibition of RhlI
by IACPs.
Alkyl-CoA Inhibition
To differentiate the contribution of the hydrocarbon tail and the ACP moieties in
binding affinity with RhlI, inhibition of enzyme activity with butyl-, hexyl-, and octylCoAs (C4-, C6-, and C8-ICoAs; compounds 92-94, respectively; Chapter 1, Table 3)
were investigated in greater detail. RhlI initial rate was observed at a fixed C4-ACP
concentration and variable ICoA concentrations (Figure 47). The IC50 values of the
ICoAs were calculated from the data (Table 19). The IC50 values of ICoAs are about one
hundred times greater than the IC50 values of corresponding IACPs: 72.7 ± 13 vs 0.74 ±
0.4 µM for C6-ICoA and C6-IACP, respectively; and 5.1 ± 0.8 vs 0.058 ± 0.02 µM for
C8-ICoA and C8-IACP, respectively. However, the sub-10 µM IC50 values for ICoAs
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and IACPs are significantly lower than most of the IC50’s obtained with AHL analogs and
no inhibition achieved with fatty acid tail alone, suggesting that ACP-pantetheine (holoACP) moieties contribute significantly to the potency of the binding affinity. (Appendix
Figure C15)

Figure 47.
IC50 test of various ICoAs. The initial rate of RhlI with 300 µM of SAM
and 14 µM of C4-ACP in the presence of varying concentrations of (a) C6- and (b) C8ICoAs were determined.

Table 19.
Effect of ICoA on RhlI initial enzyme rate with fixed C4 -ACP
concentration.
ICoA
C4-ICoA
C6-ICoA
C8-ICoA

IC50 (µM)
None up to 1 mM
72.7 ± 13
5.1 ± 0.8

Conclusion
This project represents the first effort to use AHL-based small molecules as
modulators of AHL-synthases.
We hypothesize that acyl-homoserine lactone based inhibitors would be quorum
sensing-specific inhibitors binding to both acyl-chain binding pocket and SAM binding
site. By varying headgroup polarity and chirality along with acyl-chain size and

90
substitution, we have identified key characteristics to improve inhibition and activation
(Figure 48). A long or bulky acyl-chain with headgroup of increased hydrophobicity and
D-stereocenter is required to inhibit RhlI. A slightly more hydrophobic headgroup with
D-stereocenter acylated with 3-oxoacyl-chain of medium-long length (6-10 carbons long)
yielded the best activators of RhlI. We also found that the fatty acid tail group and the
headgroup cannot independently inhibit RhlI activity. Second generation of AHL-based
modulators of RhlI activity could include bicyclic headgroups with various substitutions
to better fine-tune the levels of hydrophobicity and probe yet-to-be-identified
characteristics of the headgroup binding sites.

Figure 48.
Moieties of interest for improved AHL-based RhlI modulators.
Inhibitors (a): hydrophobic headgroup with D-stereocenter acylated with long chain;
Activators (b): long 3-oxoacyl-chain attached to hydrophobic headgroup with Dstereocenter.
The discovery of AHL-based small molecule inhibitors of RhlI is promising.
Since antibiotic resistance is often a QS-controlled phenotype, QS inhibitor with limited
potency could be used as a combination drug to reduce antibiotic resistance to further the
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usability of currently available drugs. Furthermore, if AHL analogs could target both RhlI
and RhlR, its inhibition potency could be significantly heightened to make it a viable QS
inhibitor. Therefore, despite the failure of the current library of AHL analogs to inhibit
RhlI with sub-micromolar IC50, AHL-based modulators of quorum sensing merit further
research.
However, focusing strictly on AHL synthase inhibition, AHL-analogs were
heavily outcompeted. Although targeting acyl-chain and SAM binding sites with AHL
analogs allow for QS-specific modulation, fatty-acid, IACP, and ICoA inhibition data
suggest that much greater binding energy is associated with the pantetheine and ACP
binding sites (Figure 49). To maximize both specificity and potency, the next generation
of AHL synthase inhibitors could be designed to target SAM binding site with ACP or
pantetheine binding sites.

Figure 49.
Specificity vs. Potency in targeting RhlI. Acyl-ACP and SAM are
commonly used substrates in human enzymes; therefore, (a) by targeting both acyl-chain
binding pocket and SAM binding site, AHL-synthase-specific inhibitor could be
designed. However, this study has demonstrated that (b) the pantetheine and ACP binding
sites need to be targeted for more potent inhibition of RhlI.
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We proposed two hypotheses to explain the trends we see with aliphatic-chain
length and RhlI activity. As the acyl-chain length increases, the IC50, Ki, and percent
inhibition all decrease for AHL-based RhlI inhibitors while Km and kcat decreases for
corresponding acyl-ACP substrates. The decrease in Km was much steeper than the
decrease in kcat for longer-chain acyl-ACP substrates, leading to an increase in catalytic
efficiencies for longer-chain non-native substrates relative to C4-ACP. In addition, as the
alkyl-chain length increases, inhibition increase as observed by significant decreases in
IC50 and Ki values for the longer-chain analogs; however, the percent inhibition also
decreased. This acyl-chain pattern could be due to higher koff rate and even higher kon rate
for longer-chain compounds binding to RhlI. Higher koff rate would cause less potent
effect (lower overall inhibition) while higher kon rate would cause the Ki value to
decrease, indicative of higher binding affinity. However, this trend could be caused by
the presence of an alternative acyl-chain binding site (or allosteric site). That all the
inhibitors discovered in this study were partial inhibitors suggests allosteric inhibition.
This proposal of a possible alternate acyl-chain binding site is further supported by the
presence of activators. If the 3-oxoacyl-chains of the activators were to bind with the
acyl-chain binding pocket, as indicated by hypothesis 1, it would inhibit C4-ACP
binding; however, under hypothesis 2, the 3-oxoacyl-chains would bind with the alternate
site. The binding could cause changes to RhlI tertiary structure and form a structural
configuration more favorable for catalysis to occur. Furthermore, hypothesis 2 raises
another question: how could long-chain derivates binding to one allosteric site cause both
activating and inhibiting behaviors? We hypothesize that these effects could be due to
either a) the carbonyl at the C3 position alters the mode of binding for activators
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compared with inhibitors; or (b) there could be more than one allosteric site, one for
inhibition and another for activation. Co-crystal structures of activators and inhibitors
complexed with RhlI should provide light on some of these unanswered questions.
Although we have not found a submicromolar inhibitor for AHL synthase in this thesis
yet, our research efforts on AHL derivatives as potential quorum sensing modulators
should open new doors to develop quorum sensing specific inhibitors for pathogenic
bacteria. In conclusion, the combination of scarcity of antibacterials in the drug pipeline,
increasing resistance to antibiotics, and favorable pharmaceutical qualities of AHL
derivatives as novel antivirulent molecules merit further research in this area.
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Mass Spectra

Figure A1.

Mass Spectrum of Compound 56
C8H13NO2S
Expected m/z [M + H+]: 188.0734, observed: 188.0763; relative mass error: 15.28 ppm;
Expected m/z [M + Na+]: 210.0554, observed: 210.0589; relative mass error: 16.81 ppm

Figure A2.

Mass Spectrum of Compound 57
C10H17NO2S
+
Expected m/z [M + H ]: 216.1047, observed: 216.1099; relative mass error: 23.94 ppm;
Expected m/z [M + Na+]: 238.0867, observed: 238.0942; relative mass error: 31.63 ppm
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Figure A3.

Mass spectrum of Compound 58
C12H21NO2S
+
Expected m/z [M + H ]: 244.1360, observed: 244.1405; relative mass error: 18.32 ppm;
Expected m/z [M + Na+]: 266.1180, observed: 266.1232; relative mass error: 19.66 ppm;
Expected m/z [M + K+]: 282.0919, observed: 282.0962; relative mass error: 15.21 ppm

Figure A4.

Mass Spectrum of Compound 59
C14H25NO2S
Expected m/z [M + H+]: 272.1673, observed: 272.1720; relative mass error: 17.17 ppm;
Expected m/z [M + Na+]: 294.1493, observed: 294.1555; relative mass error: 21.18 ppm;
Expected m/z [M + K+]: 310.1291, observed: 310.1291; relative mass error: 19.00 ppm
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Figure A5.

Mass Spectrum of Compound 60
C16H29NO2S
Expected m/z [M + H+]: 300.1986, observed: 300.2042; relative mass error: 18.56 ppm;
Expected m/z [M + Na+]: 322.1806, observed: 322.1872; relative mass error: 20.58 ppm;
Expected m/z [M + K+]: 338.1545, observed: 338.1605; relative mass error: 17.72 ppm

Figure A6.

Mass Spectrum of Compound 61
C10H15NO3S
Expected m/z [M + H+]: 230.0845, observed: 230.0896; relative mass error: 21.99 ppm;
Expected m/z [M + Na+]: 252.0665, observed: 252.0729; relative mass error: 25.46 ppm;
Expected m/z [M + K+]: 268.0404, observed: 268.0452; relative mass error: 17.83 ppm
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Figure A7.

Mass Spectrum of Compound 62
C12H19NO3S
+
Expected m/z [M + H ]: 258.1158, observed: 258.1162; relative mass error: 1.39 ppm;
Expected m/z [M + Na+]: 280.0978, observed: 280.1008; relative mass error: 10.77 ppm;
Expected m/z [M + K+]: 296.0717, observed: 296.0723; relative mass error: 1.95 ppm

Figure A8.

Mass Spectrum of Compound 63
C14H23NO3S
+
Expected m/z [M + H ]: 286.1471, observed: 286.1472; relative mass error: 0.21 ppm;
Expected m/z [M + Na+]: 308.1291, observed: 308.1320; relative mass error: 9.46 ppm;
Expected m/z [M + K+]: 324.1030, observed: 324.1035; relative mass error: 1.47 ppm
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Figure A9.

Mass Spectrum of Compound 64
C16H27NO3S
Expected m/z [M + H+]: 314.1784, observed: 314.1791; relative mass error: 2.10 ppm;
Expected m/z [M + Na+]: 336.1604, observed: 336.1633; relative mass error: 8.68 ppm;
Expected m/z [M + K+]: 352.1343, observed: 352.1354; relative mass error: 3.06 ppm

Figure A10. Mass Spectrum of Compound 88
Expected m/z [M + 5H+]: 1781.9, observed: 1781.7;
Expected m/z [M + 6H+]: 1485.1, observed: 1484.9;
Expected m/z [M + 7H+]: 1273.1, observed: 1273.1;
Expected m/z [M + 8H+]: 1114.1, observed: 1113.9;
Expected m/z [M + 9H+]: 990.4, observed: 990.3;
Expected m/z [M + 10H+]: 891.5, observed: 891.4
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Figure A11. Mass Spectrum of Compound 89
Expected m/z [M + 5H+]: 1787.5, observed: 1787.5;
Expected m/z [M + 6H+]: 1489.8, observed: 1489.6;
Expected m/z [M + 7H+]: 1277.1, observed: 1277.1;
Expected m/z [M + 8H+]: 1117.6, observed: 1117.6;
Expected m/z [M + 9H+]: 993.5, observed: 993.5;
Expected m/z [M + 10H+]: 894.3, observed: 894.2

Figure A12. Mass Spectrum of Compound 90
Expected m/z [M + 5H+]: 1793.1, observed: 1792.9;
Expected m/z [M + 6H+]: 1494.5, observed: 1494.2;
Expected m/z [M + 7H+]: 1281.1, observed: 1281.1;
Expected m/z [M + 8H+]: 1121.1, observed: 1120.9;
Expected m/z [M + 9H+]: 996.6, observed: 996.5;
Expected m/z [M + 10H+]: 897.1, observed: 897.0
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Figure A13. Mass Spectrum of Compound 91
Expected m/z [M + 5H+]: 1798.7, observed: 1798.5;
Expected m/z [M + 6H+]: 1499.1, observed: 1499.1;
Expected m/z [M + 7H+]: 1285.1, observed: 1285.1;
Expected m/z [M + 8H+]: 1124.6, observed: 1124.6;
Expected m/z [M + 9H+]: 999.8, observed: 999.7;
Expected m/z [M + 10H+]: 899.9, observed: 899.8

Figure A14. Mass Spectrum of Compound 92
C25H44N7O16P3S
+
Expected m/z [M + H ]: 824.1851, observed: 824.1835; relative mass error: -1.92 ppm;
Expected m/z [M + Na+]: 846.1670, observed: 846.1657; relative mass error: -1.57 ppm;
Expected m/z [M + 2Na+ - H+]: 868.1490, observed: 868.1472; relative mass error: -2.04
ppm
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Figure A15. Mass Spectrum of Compound 93
C27H48N7O16P3S
Expected m/z [M + H+]: 852.2164, observed: 852.2147; relative mass error: -1.98 ppm;
Expected m/z [M + Na+]: 874.1983, observed: 874.1953; relative mass error: -3.47 ppm;
Expected m/z [M + 2H+]: 426.6118, observed: 426.6105; relative mass error: -3.12 ppm

Figure A16. Mass Spectrum of Compound 94
C29H52N7O16P3S
Expected m/z [M + H+]: 880.2477, observed: 880.2444; relative mass error: -3.73 ppm;
Expected m/z [M + K+]: 918.2036, observed: 918.1978; relative mass error: -6.28 ppm;
Expected m/z [M + 2H+]: 440.6275, observed: 440.6259; relative mass error: -3.59 ppm
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Figure A17. Mass Spectrum of Compound 95
C31H56N7O16P3S
+
Expected m/z [M + H ]: 908.2790, observed: 9083.2733; relative mass error: -6.26 ppm;
Expected m/z [M + 2H+]: 454.6431, observed: 454.6401; relative mass error: -6.67 ppm;
Expected m/z [M + H+ + Na+]: 465.6345, observed: 465.6300; relative mass error: -9.62
ppm
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NMR spectra

Figure B1.

D-homocysteine thiolactone 1H NMR

Figure B2.

Compound 56 1H NMR
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Figure B3.

Compound 56 COSY NMR

Figure B4.

Compound 56 HSQC NMR
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Figure B5.

Figure B6.

Compound 56 HMBC NMR

Compound 56 13C NMR
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Figure B7.

Figure B8.

Compound 57 1H NMR

Compound 57 COZY NMR
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Figure B9.

Compound 57 13C NMR

Figure B10.

Compound 58 1H NMR
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Figure B11.

Compound 58 COSY NMR

Figure B12.

Compound 58 HSQC NMR
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Figure B13.

Figure B14.

Compound 58 HMBC NMR

Compound 58 13C NMR
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Figure B15.

Figure B16.

Compound 59 1H NMR

Compound 59 COSY NMR
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Figure B17.

Compound 59 HSQC NMR

Figure B18.

Compound 59 HMBC NMR
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Figure B19.

Compound 59 13C NMR

Figure B20.

Compound 60 1H NMR
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Figure B21.

Compound 60 COSY NMR

Figure B22.

Compound 60 HSQC NMR
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Figure B23.

Figure B24.

Compound 60 HMBC NMR

Compound 60 13C NMR
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Figure B25.

Figure B26.

Compound 61 1H NMR

Compound 61 COSY NMR
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Figure B27.

Compound 61 HSQC NMR

Figure B28.

Compound 61 HMBC NMR

Figure B29.

Compound 61 13C NMR

124

Figure B30.

Figure B31.

Compound 62 1H NMR

Compound 62 COSY NMR
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Figure B32.

Compound 62 HSQC NMR

Figure B33.

Compound 62 HMBC NMR

Figure B34.

Compound 62 13C NMR
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Figure B35.

Figure B36.

Compound 63 1H NMR

Compound 63 COSY NMR
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Figure B37.

Compound 63 HSQC NMR

Figure B38.

Compound 63 HMBC NMR

Figure B39.

Compound 64 13C NMR
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Figure B40.

Figure B41.

Compound 64 1H NMR

Compound 64 COSY NMR
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Figure B42.

Compound 64 HSQC NMR

Figure B43.

Compound 64 HMBC NMR

Figure B44.

Compound 64 13C NMR
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UV-Vis Spectra

Figure C1. IC50 of First generation of AHL analogs.
(Corresponds to Figure 27, Chapter 3)
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Figure C2. IC50 of L-HSL derivatives.
(Corresponds to Figure 28, Chapter 3)
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Figure C3. IC50 of acyl-D-HSL analogs.
(Corresponds to Figure 29, Chapter 3)

Figure C4.

IC50 and EC50 of 3-oxoacyl-D-HSL analogs.
(Corresponds to Figure 30, Chapter 3)
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Figure C5. IC50 of DL-sulfonamide analog.
(Corresponds to Figure 31, Chapter 3)
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Figure C6.

IC50 of acyl- and 3-oxoacyl-L-homocysteine thiolactones.
(Corresponds to Figure 32, Chapter 3)
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Figure C7.

IC50 and EC50 of acyl- and 3oxoacyl-D-homocysteine thiolactones.
(Corresponds to Figure 33, Chapter 3)

Figure C8. IC50 of cyclopentyl derivatives.
(Corresponds to Figure 34, Chapter 3)
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Figure C9. IC50 of non-lactone AHL analogs.
(Corresponds to Figure 35, Chapter 3)

138

Figure C10. IC50 of headgroup and tail moieties.
(Corresponds to Figure 36, Chapter 3)
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Figure C11. Substrate-velocity curve of RhlI with various acyl-ACP substrates.

Figure C12. IC50 of various alkyl-ACPs.
(a) C4-IACP, (b) C6-IACP, (c) C8-IACP, (d) C10-IACP
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Figure C13. RhlI Inhibition assays with various alkyl-ACPs.
(a) C4-IACP, (b) C6-IACP, (c) C8-IACP, (d) C10-IACP

Figure C14. Double reciprocal plot for RhlI inhibition with various alkyl-ACPs.
(a) C4-IACP, (b) C6-IACP, (c) C8-IACP, (d) C10-IACP
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Figure C15. IC50 of IACPs at different time points
C4-IACP and (b) C8-IACP

Figure C16. IC50 of ICoA derivatives.

Figure C17. DMSO Inhibition
RhlI activity was not inhibited up to 10% DMSO (by volume)

